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ATP-CITRATE LYASE LINKS CYCLIN E TO CELLULAR METABOLISM
IN BREAST CANCER
Kimberly S. Lucenay, B.A.
Advisory Professor: Khandan Keyomarsi, Ph.D.

Cyclin E is altered or overexpressed in approximately one-third of tumors from patients
with invasive breast cancer and is a powerful independent predictor for survival in
women with stage I-III breast cancer. Full-length cyclin E (EL) is post-translationally
cleaved into two low-molecular-weight isoforms, LMW-E (T1) and LMW-E (T2). LMWE have been shown to exhibit greater binding affinity for cyclin-dependent kinase 2
(CDK2) , cyclin dependent kinase inhibitors (CKIs), p21 and p27, but are resistant to
p21 and p27 inhibition. In addition, transgenic mice expressing LMW-E have increased
mammary tumor development and metastasis compared to EL transgenic mice.
Therefore, LMW-E are more aggressive in cell cycle abrogation and mammary tumor
development. The LMW-E isoforms are tumor specific and accumulate in the
cytoplasm due to lack of a nuclear localization sequence (NLS). Therefore, we
hypothesized that aberrant localization of LMW-E isoforms leads to molecular events
that ultimately contribute to LMW-E breast cancer tumorigenicity. To address this
hypothesis, we used a retrovirus-based protein complementation assay (RePCA) to
identify LMW-E (T1) protein-protein interactions in breast cancer. Using this
methodology, we found ATP-citrate lyase (ACLY) as a novel interacting protein of
LMW-E (T1) in the cytoplasm. ACLY is a 125kDa homotetrameric enzyme that
catalyzes cytoplasmic citrate to acetyl-CoA and oxaloacetate in the de novo lipogenesis
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pathway. End products of this pathway consist of complex fatty acids that fuel
membrane production of highly proliferating cells and lipid-based post-translational
modifications that mediate protein-protein interactions. Additionally, we found that
LMW-E upregulates ACLY enzymatic activity which leads to lipid droplet formation;
thereby providing cells with essential building blocks to support growth. ACLY is also
required for LMW-E mediated transformation, migration and invasion in vitro, as well as
tumor growth in vivo. Taken together these data suggest a novel interplay between
LMW-E and ACLY and how metabolic pathways and the cell cycle are linked in breast
cancer tumorigenesis.
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CHAPTER 1: INTRODUCTION TO THE LINK BETWEEN BREAST CANCER AND
THE CELL CYCLE

1.1 OVERVIEW OF BREAST CANCER
1.1a. Breast cancer statistics
Breast cancer is the most frequently diagnosed cancer in women with 1 in 8
women developing the disease over the course her lifetime and an estimated 231,840
new cases in 2015 alone [1]. Moreover, breast cancer in women continues to be a
leading cause of cancer death, falling second to cancer of the lung and broncus [1].
Breast cancer develops when normal, healthy mammary cells acquire mutations, or
abnormal changes that lead to uncontrolled growth. However, a genetic predisposition
is responsible for only 5-10% of all breast cancers leaving 85-90% of breast cancers to
arise sporadically [2]. Significant advances have been made in the identification of the
genetic drivers of hereditary breast cancer, including BRCA1, BRCA2, CHEK2, ATM
PALB2, p53 and PTEN mutations [2-5], but identification of the molecular mechanisms
underlying sporadic breast cancer remain largely elusive for this complex disease.
1.1b. Molecular subtypes of breast cancer
Breast cancer is a heterogeneous disease composed of several molecular
subtypes harboring distinct prognosis and outcomes. Clinical variables, on their own,
such as tumor grade, tumor size and lymph node status are not sufficient to determine
prognosis, therefore, determination of the molecular state of the tumor is required to
drive treatment decisions [6]. A patient’s overall prognosis is largely dependent on the
molecular profile of the tumor itself. Studies analyzing gene expression using DNA
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microarrays were able to segregate and differentiate breast cancers based on their
unique gene expression profile [7]. Data from this seminal paper lead to our current
system in subtyping breast cancer. At this time, there are six molecular subtypes of
breast cancer: Luminal A, Luminal B, HER2-enriched, Basal-like (which includes triplenegative breast cancer “TNBC” and its relative subtypes), Claudin-low and normal-like.
Luminal A breast cancer originates in the inner (luminal) cells of the mammary
ducts and is the most common breast cancer subtype [8, 9]. It is characterized by
estrogen receptor positivity (ER+), and/or progesterone receptor positivity (PR+) and
negative expression of human epidermal growth factor receptor 2 (HER2-) (Table 1).
Luminal A tumors have a low proliferation rate as seen by Ki67-/low staining [7, 10]. The
prevalence of luminal A breast cancer is 28-31% and while the relapse rate is 27.8%,
overall, patients have a good prognosis with a 5-year survival rate of 95%, which is the
highest of all the intrinsic subtypes [8, 11, 12]. Treatment for luminal A tumors usually
requires only endocrine therapy. Interruption of the estrogen-signaling pathway has
proven to be the most effective treatment for luminal A breast cancer. Selective
estrogen receptor modulators (SERMs) such as tamoxifen; which inhibit the function of
ER are given to premenopausal and postmenopausal patients and selective estrogen
receptor down-regulators (SERDs) such as fulvestrant are given to postmenopausal
patients [13, 14]. Additionally, postmenopausal patients may be given aromatase
inhibitors such as anestrozole, exemestane or letrozole which block estrogen
production or inactivate ER [8, 15]. However, luminal A tumors often become resistant
to endocrine-based therapy and alternate treatment strategies are being developed
[12]. The insulin-like growth factor-1 (IGF-1) and vascular endothelial growth factor
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Table: 1 The six molecular subtypes of breast cancer
Subtype Expression profile Prognosis
Prevalence
Luminal A

ER+ and/or PR+
HER2Low Ki67

Luminal B

ER+/or PR+
HER2+/or HER2with Hi Ki67

HER2enriched

Basal-like

Claudin-low

Normal-like

ER-/PRHER2+
Hi KI67

ER-/PR-HER2EGFR
Cytokeratin5/6

ER-/PR-HER2Ki67 low
Claudin3,4,7 low
CD44+/CD24 /-low
EpCam-/low
N/A

Good

Poor

Poor

28-31%

19-23%

12-21%

Treatment
Hormone
therapy

Hormone
therapy and/or
chemotherapy
Targeted
therapy
(Trastuzumab,
Lapatinib)
Combination
of surgery,
radiation and
chemotherapy

Poor

11-23%

Poor

7-14%

Chemotherapy

3-10%

N/A

Good

(+): positive
(-): negative
Adapted from:
1. Perou, C.M., T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross,
H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L.
Borresen-Dale, P.O. Brown, and D. Botstein, Molecular portraits of human breast tumours. Nature,
2000. 406(6797): p. 747-52.
2. Eroles, P.a.L., Ana et al., Molecular biology in breast cancer: Intrinsic subtypes and signaling
pathways. Cancer Treatment Reviews, 2012. 38: p. 698-707.
3. Carey, L., Perou, CM and Millikan, RC et al., Race, breast cancer subtypes, and survival in the
Carolina breast cancer study. Journal of the American Medical Association, 2006. 295(21): p. 2492
2502.
4. Prat A, a.P.C., Deconstructing the molecular portraits of breast cancer. Molecular Oncology, 2011. 5:
p. 5-23.
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(VEGF) signaling pathways have been shown to contribute to resistance and
treatments using an anti-VEGF antibody, bevacizumab, along with the
chemotherapeutic, paclitaxel, has been effective [16-18].

Additional therapies

targeting VEGFR1, VEGFR2, KIT and PDGFR combined with tamoxifen treatment
have been shown to effectively reduce tumor volume [19].
Luminal B breast cancer is similar to luminal A breast cancer in that it originates
from the luminal cells of the mammary duct and is ER+ and/or PR+. However, luminal
B breast tumors can either be HER2- or HER2+ and display an elevated proliferation
rate as seen by high Ki67 staining [7, 8]. The prevalence of luminal B breast cancer is
19-23% and has a higher recurrence rate than luminal A breast cancer [11]. Overall,
luminal B breast cancer is more aggressive and leads to a worse prognosis for patients
due to its high proliferative capacity and higher histological grade [8].
Current treatment strategies for luminal B breast cancer rely on chemotherapy,
endocrine therapy and aromatase inhibitors, but deciding on a treatment regimen can
often be convoluted due to the heterogeneity of the tumor, innate chemotherapy
insensitivity and resistance to endocrine therapy. Therefore, there are a few diagnostic
tools that have been developed over the years that are commercially available to help
drive treatment decisions. One type of diagnostic tool is Oncotype DX. Oncotype DX
was developed by Genomic Health, Inc. and is used for women with early stage ER+
breast cancer [20]. This test helps estimate the likelihood of disease recurrence and
also helps define benefits from chemotherapy [20]. Oncotype DX analyzes gene
expression levels from 16 cancer-related genes and normalizes their expression to five
background genes in order to determine a Recurrence Score between 0-100 for the
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patient [20]. For example, Paik et al. and colleagues found that node-negative ER+
breast cancer patients with a high Recurrence Score were likely to benefit from a
chemotherapy regimen such as cyclophosphamide/methotrexate/fluorouracil (CMF),
while a low Recurrence Score signified minimal benefit [21]. Therefore, diagnostic
tools such as Oncotype DX provide valuable information for clinicians in designing
treatment strategies for ER+ breast cancer patients.
Luminal B tumors are also subject to becoming endocrine resistant [11]. Indeed,
a study conducted by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
found that 33% of breast cancer patients treated with tamoxifen over five years are
likely to develop recurrent disease within 15 years [22, 23]. Endocrine resistance
develops by multiple mechanisms including loss of ERα protein expression, expressing
truncated forms of either ERα or ERβ, modifications made to ERα post-translationally,
or degregulation of co-activator proteins [22]. For example, overexpression of nuclear
receptor co-activator 3 (NCOA3), a co-activator of ERα, results in constitutive ERα
transcription and leads to estrogen resistance in vitro as well as in vivo [22, 24, 25].
Since endocrine resistance is a challenge, there is a focus to identify other
biomarkers and molecular pathways that drive luminal B tumors. IGF-1R (Insulin
growth factor 1 receptor) monoclonal antibodies are currently in phase I and II clinical
trial either alone as a single agent or coupled with chemotherapy [26]. Other targets
being investigated for luminal B breast cancer are FGF, PI3K and cyclin D1 [26].
Cyclin D1 is an attractive target for luminal B tumors due to its ability to drive
proliferation through interaction with CDK4/6 [27].
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Human epidermal growth factor receptor 2 or HER2 is a component of the
epidermal growth factor receptor family [28]. HER2-enriched breast cancer is
characterized by amplification of the HER2 gene located in the 17q12 chromosome and
subsequent enrichment of the HER2 protein. It is also characterized by negative
expression of ER and PR, but presents positivity for Ki67 [7, 8]. The prevalence of
HER2-enriched breast cancer is 12-21% and has a poor prognosis due to positive
lymph node status, poor tumor grade, early and frequent recurrence of the tumor, as
well as metastasis to the liver and lungs [11, 29]. Additionally, women are diagnosed at
an earlier age compared to luminal A or luminal B breast cancer and up to 40% have
p53 mutations [8, 9].
Treatment for HER2 positive breast cancer relies mainly on chemotherapy and
targeted therapies such as trastuzumab (Herceptin) and lapatinib (Tykerb).
Trastuzumab is a humanized monoclonal antibody that targets domain IV in the
extracellular domain of HER2 and prevents signal transduction [12, 30]. The
combination of trastuzumab plus chemotherapy resulted in increased response and
overall survival in HER2 positive metastatic breast cancer patients. Specifically, the
overall survival rate increased from 20.3 months to 25.1 months under combination
treatment vs. chemotherapy alone [31]. These data along with increased overall
response rates (ORR) and time to progression (TTP) rates made this regimen a firstline treatment for HER2 positive metastatic breast cancer in 1998 [31].
A derivative of trastuzumab, pertuzumab, is a monoclonal antibody that targets
domain II of HER2 and prevents dimerization [31]. Presently, the first-line treatment for
metastatic HER2 postive breast cancer resides from the results of the CLEOPATRA
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trial which combined trastuzumab plus docetaxel with or without pertuzumab [31].
Patients in the pertuzumab group displayed significant progression free survival and
overall survival [31].
Additional treatment strategies being used to target HER2+ breast cancer is the
use of antibody-drug conjugates which specifically target tumor cells to deliver cytotoxic
agents [12, 32]. Trastuzumab-emtansine (T-DM1) is currently being used in clinical
trials and combines trastuzumab and DM1, a microtubule inhibitor [33, 34]. Patients
given T-DM-1 showed an overall response rate of 25.9 to 34.5% [35].
One of the on-going challenges with HER2+ breast cancer is resistance to
HER2-targeted therapies, such as trastuzumab. It has been shown that HER2+ breast
cancer patients with metastatic disease do quite well initially with trastuzumab
treatment, but exhibit progression of the disease within at least one year [36]. There
are multiple mechanisms attributed to trastuzumab resistance, including increased
activation of PI3K/Akt pathway either by activation of other growth factor receptors like
IGF1R or by mutations in the tumor suppressor, PTEN [36]. Moreover, steric hindrance
by mucin-4 (MUC4) potentially blocks trastuzumab and HER2 from interacting [36].
Therefore, potential targets bring investigated to treat HER2 positive breast cancer with
trastuzumab resistance include inhibitors toward mTOR and PI3K pathways [30].
Another treatment option for HER2+ breast cancer patients are anti-HER2
vaccines [37]. Treating cancer with a vaccine has the potential to induce a long-lasting
immune response that could be manufactured against multiple antigens. Moreover,
with the help of memory cells within the immune system, cancer vaccines would
eliminate risk of recurrence [37]. HER2-based vaccines are currently in phase II clinical
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trial [38]. A peptide-based method, called E75, targets amino acids 369-377 in the
extracellular domain of HER2. In this trial, 195 patients were given up to six doses, with
about half receiving additional immunizations [38]. In the end, although DFS was not
statistically significant between treated and non-treated patients, risk of recurrence was
down 48% in the treated group [38]. Moreover, in node-positive patients, the
differences were greater. Specifically, patients treated with the E75 vaccine had a 53%
decrease in recurrence risk along with 24 month DFS rate of 90.2% compared to
79.1% for untreated patients [38].
Basal-like breast cancer is a very aggressive subtype of breast cancer that
arises from the basal cells or outer cells surrounding the mammary duct. Basal-like
breast tumors exhibit histological features of basal cells including positivity for high
molecular weight cytokeratins such as cytokeratin 5, 6, and 17 [8, 39]. These tumors
also express P-cadherin, caveolin 1 and 2, nestin, CD44, and EGFR, but do not
express ER, PR or HER2 and are often referred to as “triple negative” [8, 29].
However, basal-like breast cancer and triple-negative breast cancer (TNBC) are not
synonymous due to a discordance rate of up to 30% [8, 40]. A basal-like IHC profile
has been identified and has been coined the “Basal Core Group” and is based on the
expression of five markers: ER, PR, HER2, EGFR, and CK5/6. This group of markers
has 100% specificity and 76% sensitivity when identifying basal-like breast tumors [8,
41].
TNBC, on the other hand, was subtyped in 2011 by Lehmann et al. by gene
expression profiling from 21 breast cancer data sets and found that TNBC can be
stratified into 6 subtypes: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory
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(IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor
(LAR) [42]. The BL1 and BL2 subtype displayed a gene expression signature
consisting of cell cycle and DNA damage response genes and the M and MSL subtype
displayed a gene expression signature for genes involved in the epithelialmesenchymal transition and growth factor pathways. The LAR subtype displayed
expression of genes in the androgen receptor signaling pathway. More recently,
Berstein et al. also subtyped TNBC tumors from 198 patients and found only four
subtypes: Luminal–AR (LAR), mesenchymal (MES), Basal-like immune suppressed
(BLIS) and Basal-like Immune-Activated (BLIA) [43]. These two studies provide
overlap for the LAR and MES TNBC subtypes, but lack agreement on the other four
Lehmann subtypes. Nevertheless, the ongoing efforts to classify TNBC provide a
foundation for molecular-targeted therapies and treatment strategies for patients
afflicted with TNBC.
The prevalence of basal-like breast cancer is 11-23% and is more common in
premenopausal women and women of African decent [9, 11]. Unfortunately, prognosis
for basal-like breast cancer is poor due to large tumor size at presentation, high
histological grade and proliferation rate, lymph node positivity, and lack of targeted
treatment strategies [8, 44]. Surgery, chemotherapy and radiation are the main
treatment strategies for basal-like breast tumors [45]. Basal-like tumors have a high
rate of p53 mutations as well as BRCA1 mutations, both of which function in DNA
damage repair [8]. Thus, these tumors initially respond very well to chemotherapy,
however, the relapse rate is common within the first one to three years [46, 47]. In
patients with BRCA1 mutations, inhibition of PARP-1 (poly-ADP-ribose-polymerase- 1),
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which also aids in DNA repair, leads to cell death due to the accumulation of DNA
damage; a concept known as synthetic lethality. One study showed that 47% of breast
cancer patients with BRCA1 and BRCA2 mutations responded to treatment using the
PARP-1 inhibitor, Olaparib (AZD2281), and 63% showed clinical benefit from the drug
[48].
In addition to PARP inhibitors as a targeted therapy to treat basal-like breast
cancer, inhibition of EGFR is also promising due to its overexpression in TNBC [45].
However, the efficacy of the EGFR monoclonal antibody, cetuximab, is modest. A
randomized phase III trial evaluating cisplatin with and without cetuximab showed a
response rate of 20% and progression free survival extended about 2 months [49].
Other studies have investigated the efficacy of small molecule tyrosine kinase inhibitors
toward EGFR as a monotherapy with little success and may be beneficial to combine
these small molecule inhibitors with a chemotherapy regimen [50]. Lastly, other targets
being evaluated for treatment of basal-like breast cancer include c-Kit, EGFR, VEGFR,
mTOR, αβ-crystallin, Src, HDAC inhibitors, HSP90 and the JAK/STAT signaling
pathway [51, 52].
The claudin-low subtype was first discovered in 2007 by Herschkowitz et al. and
has a similar gene expression pattern to the basal-like subtype including negativity for
ER, PR and HER2, but differs from the basal-like group in that claudin-low tumors
display low expression of tight junction genes claudin 3, 4, 7 and occludin and the
intercellular adhesion gene, E-cadherin [8]. Furthermore, genes involved in the
immune response expressed by T- and B-lymphoid cells that infiltrate the tumor are
unique to the claudin-low group [53, 54]. Additionally, claudin-low tumors express
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genes related to the cancer stem cell (CSC) phenotype such as CD44+/high/CD24-/low
along with mesenchymal features such as vimentin and N-cadherin expression [11].
The prevalence of claudin-low breast cancer is 7-14% and, overall, has a poor
prognosis [11, 29]. Generally, the poor prognosis of claudin-low tumors is due to
radiation and chemotherapy insensitivity, and tumor relapse due to a residual CSC
population [11]. Specifically, in vitro studies evaluated patient breast tumor biopsies
before and after neoadjuvant chemotherapy and showed that chemotherapy increased
the percentage of CD44+/high/CD24-/low cells and these cells were more capable of
mammosphere formation; both characteristics of CSCs [55]. Therefore, identification of
signaling pathways that regulate self-renewal and thus, compounds that target these
pathways would provide a treatment strategy for claudin-low tumors. Lastly, normallike tumors have a prevalence rate of 3-10%, a gene expression profile that resembles
the normal breast and the prognosis overall is very good [11].

1.2 THE CELL CYCLE AND CANCER
1.2a. The cell cycle
The mammalian cell cycle is a series of synchronized events a single cell must
accomplish in order to divide into two daughter cells and consists of two major parts:
interphase and mitosis [56]. Interphase encompasses G1, S and G2 phases of the cell
cycle and is a period for cell growth (schematic of the mammalian cell cycle Figure 1).
G1 is the gap phase between mitosis and DNA replication in which cells grow in
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Figure 1. Schematic of the mammalian cell cycle
The mammalian cell cycle consists of 5 phases: G0, G1, S, G2 and M. Progression
though one cycle first requires growth factor stimulation and subsequent activation of
cyclin/CDK complexes. At the restriction point, the cell is fully committed to the cell
cycle and can proceed in the absence of growth factors. G1 cyclin/CDK complexes are
controlled by Cip/Kip and INK4 families of inhibitors, while cyclin B/CDK1 are tightly
controlled by phosphorylation and dephosphorylation by Cdc25 and Wee1/Myt1,
respectively.
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volume, analyze growth signals and prepare for DNA replication [57]. DNA synthesis
occurs in S phase and G2 is the gap phase between S phase and M phase in which
the cell prepares for cell division. Mitosis, or M phase, occurs just prior to cell division
when chromosomes condense, align, sister chromatids separate and cytokinesis
occurs to form two daughter cells [57]. Cells can reversibly exit the cell cycle at G0
phase and enter a quiescent or non-proliferative state when nutrients are lacking or cell
adhesion is inhibited. When conditions become more favorable quiescent cells are
able to re-enter the cell cycle [57-59]. In fact, the majority of the non-proliferating cells
in the human body are in G0 [60].
Our knowledge of the mammalian cell cycle stemmed from studies using single
cell eukaryotes and marine invertebrates [57]. Progression through the mammalian cell
cycle occurs mainly through phosphorylation events facilitated by cyclins and their
partners; cyclin-dependent kinases (CDKs) [56]. Cyclins, as their name implies,
oscillate in expression during the cell cycle and are synthesized and degraded in a
highly orchestrated fashion, while CDK protein expression remains stable [61]. To
date, there are as many as 29 cyclin or cyclin-related proteins (A1, A2, B1, B2, B3, C,
D1, D2, D3, E1, E2, F, G1, G2, H, I, J, K, L1, L2, M1, M2, M3, M4, O, T1, T2, Cables 1,
Cables 2) and are related to one another by 150 conserved amino acid residues called
‘the cyclin box’. In addition there are at least 13 CDKs (CDK1-13) [62, 63]. However,
only specific cyclin/Cdk complexes have the required kinase activity to drive the cell
cycle forward in a timely fashion (Table 2) [62, 63].
Unlike other cyclins, D-type cyclins levels do not oscillate and are controlled by
the presence or absence of growth factors [57]. Mouse knockout studies of
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Table: 2. Biological functions of cyclins and CDKs in the mammalian
cell cycle	
  
Cyclin
Biological
Cell cycle
Knockout
or
function
binding
phenotype
Viability
CDK
partner
Cyclin A

Cell cycle
(G1-S) and
(G2-M)

-A1: males are sterile due
to arrest in meiotic
prophase

CDK1
and
CDK2

-A2: Defective mitosis
-B1: Embryonic lethal
Cyclin B

Cyclin C

Cell cycle
(G2-M)

CDK1

Cell cycle
(G0-S)
Transcription

CDK3
and
CDK8

-B2: Develop normally,
males and females are
fertile.
ND*

A1: Viable
A2:
Embryonic
lethal before
E5.5
B1: Lethal at
E10.5
B2: Viable

ND*

-D1: Small body size,
hypoplastic retinopathy,
defective breast
development during
pregnancy, neuropathy
D1: Viable
-D2: Defective ovarian
granulosa cell
development and female
sterility. Males have
hypoplastic testes but are
fertile. Impaired
proliferation of peripheral
B-lymphocytes.

Cyclin D

Cell cycle
(G0-S)

CDK4
and
CDK6
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D3: Viable
D2 and D3:
Embryonic
lethal before
E18.5

-D3: Hypoplastic thymus
with loss of T-cell
maturation from (CD4,CD8-) to (CD4+, CD8+)
cells due to cytokineindependent defects in
pre-TCD signaling.

D1 and D3:
Death at P1,
but few
survive to 2
months

-D2 and D3: Severe
megaloblasticanemia

D1 and D2:
Viable, but die
within 3
weeks

-D1 and D3: Neuropathy
leading to meconium

	
  

D2: Viable

D1, D2, D3:

aspiration. Survivors fail to
thrive and exhibit
hypoplastic retinas.

Embryonic
lethal at
E16.5

-D1 and D2: Retarded
growth and impaired
coordination. Inhibited
postnatal cerebellar
development and
hypoplastic retinas.
-D1,D2,D3: Severe
hematopoietic deficits and
death due to anemia and
defects of heart
development.
-E1: Normal
E1: Viable
Cyclin E

Cell cycle
(G1-S)

-E2: Hypoplastic testes,
reduced sperm count, and
male infertility

CDK2

-E1 and E2: Cardiac
abnormalities, reduced
endoduplication in
megakaryocytes

	
  

Embryonic lethal due to
defects in placental
development.

E2: Viable
E1 and E2:
Embryos
dead by
E11.5

Cyclin F

Cell cycle
(S, G2, M)

ND*

Cyclin G

DNA damage
response

CDK5

ND*

ND*
ND*

CDK7

CDK activation,
transcription,
DNA repair

ND*

Cyclin H

Cyclin L

CDK12
and
CDK13

Transcription,
splicing

ND*

ND*

CDK12
and
CDK13

Transcription,
CDK activation

ND*

ND*

Cyclin K

Cyclin T

CDK9

Transcription

ND*

ND*
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Lethal at
E10.5

CDK1

Cell cycle
(G2-M)

CDK2

Cell cycle
(G1-S)

CDK3

Cell cycle
(interphase)

CDK4

CDK5

CDK6

Cell cycle
(G0-S)

Neuronal cell
cycle and
differentiation

Cell cycle
(G0-S)

Cyclin B

Embryonic lethal due to
defects in first cell divisions

Cyclin E
and
Cyclin A

Sterility in males and
females due to defects in
meiosis; no effect on
mitotic cells
Mutation inducing
premature stop codon
results in a normal
phenotype; most
laboratory strains carry this
mutation
-CDK4: Small body size.
Males are sterile due to
hypoplastic tested and low
sperm counts. Female
sterility due to defects in
hypothalamus and
pituitary, abnormal estrus
and failure of corpus
luteum. Abnormal
development of pancreatic
β-islet cells and insulindependent diabetes.

Cyclin C

Cyclin D

-CDK4 and CDK6: Small
embryos, partial failure of
hematopoiesis resulting
from multipotential
progenitors and
multilineage deficits.
Defective development
and structure of the
nevous system

Cyclin G

-CDK6: Thymic and
splenic hypoplasia. Mild
defects in hematopoiesis.
T-lymphocytes have delay
in S-phase entry.

Cyclin D

-CDK4 and CDK6: Small
embryos, partial failure of
hematopoiesis resulting
from multipotential
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Lethal

Viable

Viable

CDK4: Viable
CDK4 and
CDK6:
Embryonic
lethality at
E14.5 and
few live pups
die soon after
birth

Perinatal
lethality

CDK6: Viable
CDK4 and
CDK6:
Embryonic
lethality at
E14.5 and
few live pups
die soon after
birth

progenitors and
multilineage deficits.
CDK7

CDK8
CDK9
CDK10

Phosphoylate
and activate
CDKs. Controls
transcription by
phosphorylating
TFIIH and CTD
of RNA
polymerase II
Transcription
Transcription
Cell cycle
(G2-M)
and
transcription

Cyclin H

ND*

ND*

Cyclin C
Cyclin T

ND*
ND*

ND*
ND*

ND*

ND*

ND*

Essential for periimplantation of embryos
and defects in mitosis such
as centrosome maturation,
spindle formation, sister
chromatid cohesion and
cytokinesis

Lethal at E3.5

CDK11

Cell cycle
(G2-M)
and
transcription

Cyclin L

CDK12

Splicing
regulation
Splicing
regulation

Cyclin K

ND*

ND*

Cyclin K

ND*

ND*

CDK13

*Abbreviations:
ND, Not Determined
Adapted from:
1. Sherr, C.J. and Roberts, J.M. CDK inhibitors: positive and negative regulators of G1-phase
progression. Genes and Dev. 1999 (13): 1501-1512.
2. Morgan, D.O. Cyclin-dependent kinases: Engines, clocks and microprocessors. Annu. Rev. Cell Dev.
Biol. 1997. (13):261-91.
3. Johnson, D.G. and Walker, C.L. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol.
1999. (39):295- 312.
4. Sherr, C.J. and Roberts, J.M. Living with or without cyclins and cyclin-dependent kinases. Genes and
Dev. 2004. (18):2699-2711.
5. Geng, Y., Q. Yu, W. Whoriskey, F. Dick, K.Y. Tsai, H.L. Ford, D.K. Biswas, A.B. Pardee, B. Amati, T.
Jacks, A. Richardson, N. Dyson, and P. Sicinski, Expression of cyclins E1 and E2 during mouse
development and in neoplasia. Proc Natl Acad Sci U S A, 2001. 98(23): p. 13138-43.
6. Malumbres, M aand Barbacid, M. Mammalian cyclin-dependent kinases. Trends in Biochemical Sci.
2005. 30(11):630-641.
7. Malumbres, M. and Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev.
Cancer. 2009. (9):153-166.
8. Hunter, T. and Pines, J. Cyclins and cancer II: cyclin D and CDK2 inhibitors come of age. Cell. 1994
(79):573-582.
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Akashi, and P. Sicinski, Cyclin A is redundant in fibroblasts but essential in hematopoietic and embryonic
stem cells. Cell, 2009. 138(2): p. 352-65.
10. Brandeis, M., I. Rosewell, M. Carrington, T. Crompton, M.A. Jacobs, J. Kirk, J. Gannon, and T. Hunt,
Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl
Acad Sci U S A, 1998. 95(8): p. 4344-9.
11. Tetzlaff, MT, Bai C, Finegold M, Wilson J, Harper JW, Mahon KA, Elledge, SJ. Cyclin F disruption
compromises placental development and affects normal cell cycle execution. Mol. and Cell Biol. 2004.
(24)6:2487-2498.
12. Kohoutek, J and Blazek, D. Cyclin K goes with CDK12 and CDK13. Cell Div. 2012. 7(12):1-10.
P110/P58
13. Li, T. Inoue, A, Lahi, JM, Kidd, VJ et al. Failure to proliferate and mitotic arrest od CDK11
-null
mutant mice at the blastocyst stage of embryonic cell development. Mol. and Cell Biol. 2004. 24(8):31883197.
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cyclin D1, D2 and D3, collectively referred to as cyclin D, have been shown to be
functionally redundant, but have tissue specificity. Studies in mice revealed that
knockout of any two D-type cyclins results in dealth, highlighting the functional
importance this cyclin [57, 64]. Upon mitogenic stimulation cyclin D binds and activates
CDK4 and CDK6 [57, 63]. The cyclin D/CDK4/6 complex partially phosphorylates
pocket proteins Rb, p107 and p130. Rb, retinoblastoma tumor suppressor protein, is
the primary substrate of the cyclinD/CDK4/6 complex [57]. These pocket proteins are
bound to transcription factors E2F1 and DP1 that positively regulate transcription of cell
cycle genes cyclin A, cyclin E, CDK1 and cdc25 [57, 60]. The binding of Rb to E2F1
and DP1 restricts E2F1 transcriptional activity and complete inhibition of Rb and
dissociation from E2F1 is achieved by hyperphosphorylation by cyclin E/CDK2. This
results in a positive feedback loop and the ability of the cell to progress to S phase [57,
63]. In late G1 the cell reaches the restriction point, “R” or “START”, in which the cell is
no longer responsive to growth factors; and indicates that the cell is fully committed to
the cell cycle [60, 65].
Cyclin A1 and cyclin A2 (collectively referred to as cyclin A) function in S phase
to promote DNA replication. Upon entry into S phase, cyclin A first binds to CDK2 to
phosphorylate substrates involved in DNA synthesis and to drive progression through S
phase [66]. Then, cyclin A dissociates from CDK2 and binds CDK1 during G2 to
promote entry to M phase. Cyclin A degradation occurs at the end of G2 and the onset
of mitosis begins [66].
Cyclin B1 and B2 are both present in dividing mammalian cells, however cyclin
B1 is referred to as the mitotic cyclin translocates to the nucleus and binds to CDK1 to
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drive the cell through mitosis [63, 67, 68]. The stages of mitosis are prophase,
prometaphase, metaphase, anaphase, telophase and cytokinesis. Cyclin B/CDK1 aids
the mitotic process by phosphorylating more than 70 substrates involved in initiating
centrosome separation, nuclear envelope breakdown and chromosome condensation
[63]. At first, in order to prevent premature cell division, Wee1 and Myt1 kinases
phosphorylate CDK1 at tyrosine 15 and threonine 14 to inhibit its activity; then Cdc25C
dephosphorylates CDK1 at these same sites leading to its activation and allowing the
cell to progress through mitosis [60, 65]. A complete cell cycle ends with the
ubiquitination of cyclin B by the anaphase-promoting complex/cyclosome (APC/C)
leading to its degradation [57, 63]. Depending on mitogenic signals, the cell will either
go through another cell cycle or enter quiescence.
Regulation of cell cycle CDKs occurs by two families of CDK inhibitors (CKIs):
INK4 and Cip/Kip. The INK4 family consists of p15INK4b, p16INK4a, p18INK4c and p19INK4d
and function by preventing CDK4 and CDK6 binding to cyclin D [57, 60]. The INK4
proteins display approximately 40% sequence homology that comes from four
sequential ankyrin motifs [57]. p16 was initially identified in SV40 T antigen
transformed cells and found to be a binding protein and inhibitor of CDK4, but can also
inhibit CDK6 in a similar fashion [69]. Importantly, Rb can inhibit p16 gene expression
via negative feedback inhibition thus controlling cell proliferation [57]. In contrast, p15
expression is not related to Rb status, rather is induced by the growth inhibitory
cytokine, transforming growth factor- β (TGF-β) [57].
The Cip/Kip family consists of p21Cip1, p27Kip1 and p57Kip2 and mainly function to
inhibit cyclin/Cdk complexes, but also inhibit kinases not related to the cell cycle [57,
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60, 65]. p21 inhibits cyclin D/CDK4, cyclin E/CDK2 and cyclin A/CDK2, and inhibition
of cyclin/CDK complexes may require more than one p21 molecule [69]. Additionally,
proliferating cell nuclear antigen (PCNA) and other components of the DNA replication
machinery are inhibited by p21, and are therefore arrested prior to S phase to prevent
premature DNA replication [69]. p21 is transcriptionally regulated by p53, a tumor
suppressor protein, and is essential for p53-mediated arrest upon DNA damage [57,
69].
The other Cip/Kip proteins, p27 and p57, are similar to p21 in that they share a
conserved N-terminus required for cyclin/CDK inhibition [57]. Specifically, p27 controls
cell proliferation by facilitating anti-growth signals from TGF- β and proteins involved in
cell contact [57]. Whereas p21 and p27 are ubiquitously expressed, p57 is tissue
specific and plays a specialized role in controlling cell proliferation [57].
The integrity of the mammalian cell cycle is maintained by two main cell cycle
checkpoints: DNA damage checkpoint at G1/S and DNA damage checkpoint at G2/M
[63]. Genotoxic agents or environmental factors that cause DNA damage are
recognized and evaluated at the G1/S checkpoint. Here, the cell induces cell cycle
arrest in a p53-dependent manner to repair damage or if damage is too severe,
progress to apoptosis [63, 70]. The induction of p53 causes the upregulation of genes
involved in cell cycle arrest (p21), regulation of p53 (Mdm2) and apoptosis (Bax, Fas)
[60]. There are also mechanisms in place if damage occurs during DNA replication, but
these mechanisms are still being elucidated [60, 71]. Studies have shown that the
replication fork stalls due to p21 sequestering PCNA or PCNA being degraded though
ubiquitination by Rad6 [70]. The G2/M checkpoint monitors the cell for DNA damage
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before mitosis. Here, cell cycle arrest occurs through Wee1 and Myt1 kinase
upregulation and well as downregulation of Cdc25C [63, 70]. In addition, cyclin
B/CDK1 is sequestered in the cytoplasm by Cdc25A/14-3-3 proteins [70]. Lastly, there
is a checkpoint during mitosis call the ‘spindle assembly checkpoint’ [60, 63]. The
spindle assembly checkpoint ensures proper alignment and segregation of the
chromosomes [60, 63]. Ultimately, loss of checkpoint control can lead to genetic
abnormalities and overall contribute to tumorigenic processes in mammalian cells.
1.2b. Cell cycle deregulation in cancer
Cancer is largely a disease of improper cellular proliferation, but the underlying
mechanisms that permit aberrant proliferation in cancer cells are complex and
encompass decades of research [72]. Observations that the cell cycle is deregulated in
cancer resulted from the early work of Theodor Boveri. In 1889, observed that
complementary chromosomes within the nucleus are required for proper embryonic
development and reasoned that aberrant chromosomes may lead to malignant
transformtion [73]. Later, in 1971, Alfred Knudson demonstrated retinoblastoma could
be caused by as little as one mutation in each of the alleles of the retinoblastoma gene
(RB1) [74]. This important observation lead to the “two-hit hypothesis” which states
that individuals would develop familial retinoblastoma if they first have a hereditary
mutation in one RB1 allele and acquire an additional mutation in the second allele by
an environmental source. In cases of sporadic retinoblastoma, both mutations would
be acquired. Knudson’s studies were integral in establishing the idea that cancer
arises from genetic changes in either oncogenes, which acquire gain-of-function
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mutations, or tumor-suppressor genes, in the case of RB1, which acquire loss-offunction mutations [72].
Since then, molecular studies have shown that the cell cycle machinery is often
deregulated in human cancers and alterations in genes encoding proteins involved in
G1 and S phases of the cell cycle are the most common (Table 3) [75]. For example,
cyclin D1, a G1 cyclin, is amplified and overexpressed in a wide variety of human
neoplasias (Table 3). Cyclin D1, originally called PRAD1, was first identified as playing
a role in parathyroid tumorigenesis and thought to function during the cell cycle [76].
The causative role for cyclin D1 came in 1994 when Wang et al. and colleagues
overexpressed cyclin D1 in the mammary cells of transgenic mice. They found that
cyclin D1 overexpression in the mammary tissue resulted in increased proliferation and
induced the development of mammary adenocarcinomas [77]. Additionally, cyclin D2
and D3 are also overexpressed in some cancers, but their oncogenic role is not well
established [69]. Other cyclins are overexpressed or amplified in human neoplasias as
well. For example, cyclin E is amplified, overexpressed or both, in carcinomas of the
breast, colon, lung, and leukemia as well as a number of other cancers (Table 3), while
cyclin A has been shown to be altered in liver cancer by providing an insertion site for
hepatitis B virus (HBV) [57, 60, 69]. The integration of HBV at the CCNA locus
produces a chimeric protein in which the N-terminal cyclin box is replaced by the virus.
Consequently, cyclin A can no longer be degraded [69].
Moreover, cyclin D kinase partners, CDK4 and CDK6, are overexpressed in
many human cancers as a result of gene amplification, but also harbor mutations or
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Table 3: Cell cycle proteins deregulated in cancer
Deregulated
Protein
Molecular Alteration
Cancer Type

cyclin D1

Gene amplification,
overexpression

cyclin D2

Overexpression

cyclin D3

Overexpression

cyclin E1

Gene amplification,
overexpression

cyclin A

Overexpression, altered

CDK2

Overexpression

CDK4

CDK6

Rb

p15

INK4B

p16INK4A
	
  

Breast, lung, pancreas,
gastrointestinal, endometrium,
bladder, bone marrow (leukemia),
head and neck, lymphoma,
melanoma, liver, pituitary, prostate,
testis/ovary, other sarcomas
Gastrointestinal, lymphoma,
testis/ovary
Pancreas, pituitary, lymphoma
Glioblastoma, breast, lung,
gastointestinal, endometrium,
bladder, bone marrow (leukemia),
lymphoma, melanoma, liver,
prostate, testis/ovary, bone, other
sarcomas
Liver
Gastrointestinal, liver

Glioblastoma, breast, lung,
Gene amplification,
endometrium, bone marrow
overexpression, mutations (leukemia), head and neck, liver,
resulting in lack of CKI
testis/ovary, bone
binding
Gene amplification,
overexpression,
mutations/translocation
resulting in lack of CKI
binding

Deletion, missense
mutation

Glioblastoma, lymphoma, other
sarcomas

Glioblastoma, breast, lung,
endometrium, bladder, bone marrow
(leukemia), lymphoma, liver,
pituitary, prostate, testis/ovary, bone
Glioblastoma, lung, bone marrow
(leukemia), lymphoma, liver

Deletion
Deletion, mutation
24	
  

Glioblastoma, lung, pancreas,

gastrointestinal, endometrium,
bladder, bone marrow (leukemia),
head and neck, melanoma,
lymphoma, liver, pituitary, prostate,
testis/ovary, bone, other sarcomas
Glioblastoma, breast, lung,
pancreas, gastrointestinal,
endometrium, bladder, bone marrow
(leukemia), head and neck,
lymphoma, liver, pituitary, prostate,
testis/ovary, other sarcomas

p27KIP1

Deletion

Cdc25B

Overexpression

Breast

Adapted from:
1. Malumbres, M. and M. Barbacid, To cycle or not to cycle: a critical decision in cancer. Nat Rev.
Cancer,2001. 1(3): p. 222-31.
2. Vermeulen, K., D.R. Van Bockstaele, and Z.N. Berneman, The cell cycle: a review of regulation,
deregulation and therapeutic targets in cancer. Cell Prolif, 2003. 36(3): p. 131-49.
3. Schafer, K.A., The cell cycle: a review. Vet Pathol, 1998. 35(6): p. 461-78.
4. Johnson, D.G. and C.L. Walker, Cyclins and cell cycle checkpoints. Annu Rev Pharmacol Toxicol,
1999. 39: p. 295-312.
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translocations rendering them insensitive to inhibition by CKIs (Table 3) [57].
Specifically, in neuroblastoma cell lines, mutations found in CDK6 prevent p16INK4A
interaction, but preserve its kinase activity, leading to unrestricted phosphorylation of
pRb [78].
Cyclin dependent kinase inhibitors are an important class of tumor
suppressors and are often either mutated or deleted entirely in human tumors (Table
3). Interestingly, the p16INK4A locus is a close second to p53 in terms of genetic
aberrations [57, 60]. Mutated p16 is linked to familial melanoma syndrome and
deletions have also been described in nearly 50% of gliomas and mesotheliomas, 4060% gastrointestinal cancers and 20-30% acute lymphoblastic leukemias [57, 60].
Located in close proximity to the p16 locus, is p15 and is often deleted concurrently
[60]. p27 is also found to be deleted or downregulated in many human cancers,
including lung, breast and bladder and its loss is implicated with poor prognosis and
aggressive disease [60]. On the other hand, in colorectal cancer, p27 loss is due to
increased proteolysis by the proteasome [60]. Although p21 is not directly altered in
tumors, p21 is a transcriptional target of p53 and p53 is the most common mutated
gene in human cancer [57, 60]. Therefore, upon DNA damage, inactive p53 cannot
activate p21 to induce cell cycle arrest, thus leading to genomic instability.
The culmination of alterations in G1 and S phase proteins in human cancer
highlights the importance of integrity of the cell cycle prior to the Restriction Point. As
previously mentioned, the Restriction Point is defined as the threshold in G1 in which
cells can proliferate in the absence of growth factors. Cells that lose function of G1
inhibitors (CKIs) and/or gain of function of G1/S drivers such as cyclin D1 or cyclin E
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have unrestricted access through this critical checkpoint. Rb is the key regulator of the
Restriction Point and is commonly deleted or mutated [65]. Upon inactivation of Rb by
deletion, mutation or hyperphosphorylation by G1 cyclin/CDK complexes, Rb releases
transcriptional repression of E2F leading to transcriptional activation of cell proliferation
genes such as cyclin A, cyclin E, CDK1, Cdc25 and c-myc [57, 69]. Rb is kept in the
hyperphosphorylated state by cyclin E/CDK2 creating a positive feedback loop and
driving the cell through the Restriction Point and fully committing the cell to cell division
[57].
1.3 CYCLIN E
1.3a. Regulation of cyclin E levels
Human cyclin E was first discovered in 1991 through screening of human cDNA
libraries for genes that would substitute for mutated G1 cyclins in yeast [79]. There are
two E-type cyclins, cyclin E1 and cyclin E2, and display 47% sequence homology
throughout the entire gene and 75% sequence homology within the cyclin box [80].
The majority of studies on cyclin E are on cyclin E1 (generally referred to as cyclin E in
this dissertation) and cyclin E2 will be addressed specifically as cyclin E2. Full length
cyclin E is found on chromosome 19q12-q13, is 409 amino acids in length, and
contains numerous regulatory domains (Figure 2) [81, 82]. The MRAIL motif is a
hydrophobic stretch of amino acids within the cyclin box that facilitates the recognition
of RXL motif containing substrates or CKIs (Figure 2) [82]. The “cyclin box” as well as
the last 50 amino acids of cyclin E aid in CDK2 binding and activation. The VDCLE
motif is responsible for Rb binding as well as pocket proteins p107 and p130 (Figure 3)
[82].
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Figure 2. Schematic of human cyclin E1
The known phosphorylation sites of human cyclin E1 are shown in pink circles at their
specific amino acid location along with its respective kinase. Known regulatory motifs
of cyclin E such as MRAIL and VDCLE are indicated as well as the conserved cyclin
box and PEST domain. (Figure adapted from Hwang, H.C. and B.E. Clurman, Cyclin
E in normal and neoplastic cell cycles. Oncogene, 2005. 24(17): p. 2776-86).
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Expression of cyclin E oscillates throughout the cell cycle and peaks at the G1/S
transition [81, 82]. Transcriptional control of cyclin E is mediated by E2F. As
previously stated in section 1.2a, E2F transcriptional activity is repressed by pRb and
pocket proteins p107 and p130. Upon mitogenic signaling, cyclin D/CDK4/6 complexes
partially phosphorylate Rb, therefore activating E2F [81]. E2F activation results in the
transcription of S phase genes as well as the transcription of cyclin E. The promoter of
cyclin E contains an E2F binding site, and thus, cyclin E can positively regulate its own
transcription through a positive feedback loop and reinforce Rb inactivation [81].
Interestingly, cyclin E transcription independent of E2F activation has also been
described [83]. However, this phenomenon may be cell type specific. For example, in
pancreatic and hepatic cells, cyclin E is transcribed by LRH-1 [84].
The degradation of cyclin E occurs by two different mechanisms and is based on
whether cyclin E is bound to CDK2. Proteolysis of monomeric cyclin E in mediated by
Cul-3, however the exact mechanisms of degradation are still being elucidated [81, 82].
The second method of cyclin E degradation is through the SCF-Fbw7 pathway and
degrades the cyclin E when bound to CDK2. The SCF-Fbw7 complex is comprised of
SKP-1, CDC53/Cullin, Rbx1/Roc1, CDC34 and Fbw7 [82]. Ubiquitination of cyclin E
occurs in the “PEST-box” or “destruction-box” [82]. For cyclin E to be degraded by the
SCF complex, cyclin E must be phosphorylated at T380 and S384 (Figure 2). The
former is phosphorylated by GSK3β or CDK2, while the latter is an autophosphorylation
site of cyclin E/CDK2 [81, 82]. Phosphorylation of T62 assists in binding Fbw7 to
mediate degradation as well. In vitro studies by Koepp et al. and collegues in 2001
showed that mutation of T380 and T62 prevent Fbw7 binding to cyclin E resulting in its
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stability [85]. S372 is also thought to play a role mediating cyclin E stability, but the
exact mechanism is unknown and more investigation is required [81].
Additional regulation of the cyclin E/CDK2 complex comes from the CKIs such
as p21 or p27. p21 and p27 inhibit the kinase activity of the cyclin E/CDK2 complex
and therefore the cyclinE/CDK2 complex does not display the appropriate signal to
SCF-Fbw7 for degradation [81]. Lastly, cyclin E is able to avoid degradation by
localizing to alternative subcellular compartments (discussed in section 1.3d) [81].
Although not completely understood, proteolysis of cyclin E2 occurs in a similar fashion
as cyclin E. Specifically, cyclin E2 is degraded by the proteasome and is stabilized by
phosphorylation at T392 (T380 in cyclin E) [81].
1.3b. Cyclin E function
The primary function of cyclin E/CDK2 is to promote cell cycle progression
through the Restriction Point into S phase by further phosphorylating Rb. As stated
previously, full inactivation of pRb by cyclin E/CDK2 results in transcriptional activation
of E2F and enables transcription of S phase related genes such as thymidine kinase,
polymerase α, MCM, Cdc6, b-myb, cyclin E, cyclin A and Histone H1 [82]. Moreover,
cyclin E/CDK2 is able to phosphorylate p21 and p27, thereby promoting their
degradation by the proteasome pathway and releasing inhibition of cyclin A (Figure 3)
[81, 82, 86, 87].
For the cell to properly progress to S phase, cyclin E also participates in DNA
replication origin licensing during DNA synthesis. Cyclin E and Cdc6 work together
along with PCNA and polymerase α to load MCM proteins and Cdc45 to the origins of
replication (Figure 3) [81, 82]. However, these fundamental functions of cyclin E were
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Figure 3. Functions of cyclin E and known substrates
Cyclin E functions and known substrates are shown. Cell cycle related functions are
highlighted in green and non cell cycle related functions are highlighted in blue. Cyclin
E/CDK2 substrates known to be associated with each respective function are shown on
the arrow. (Figure adapted from: Hwang, H.C. and B.E. Clurman, Cyclin E in normal
and neoplastic cell cycles. Oncogene, 2005. 24(17): p. 2776-86; Moroy, T. and C.
Geisen, Cyclin E. Int J Biochem Cell Biol, 2004. 36(8): p. 1424-39; Siu,K.T.,M.R.
Rosner, and A.C. Minella, An integrated view of cyclin E function and regulation. Cell
Cycle, 2012. 11(1): p. 57-64.)
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challenged in 2003 when Geng et al. created a cyclin E knockout mouse [88].
Surprisingly, the authors showed that cyclin E is largely unnecessary for development
in the mouse. However, the authors did find that cyclin E is required for endoreplication
of placental trophoblast giant cells and megakaryocytes [81]. Additionally, cyclin E null
mice are deficient re-entering the cell cycle from quiescence as well as defective in
loading MCM proteins at the origins of replication [88].
Another function of cyclin E is centrosome duplication. Specifically, cyclin
E/CDK2 phosphorylates NPM/B23 (nucleophosmini B23) on T199 to facilitate the onset
of centrosome duplication (Figure3) [81]. CP110 is also phosphorylated by cyclin
E/CDK2 and is involved in duplication and separation of chromosomes [87]. Moreover,
cyclin E participates in the regulation of the cell cycle transcriptional program.
Transcription factors known to be regulated by cyclin E/CDK2 are Id2, Id3, BAF155 and
SWI/SNF [82]. Cyclin E/CDK2 also phosphorylates CBP/p300, resulting in activation of
its histone acetyltransferase activity, and E2F5 to promote transcriptional activation
assisting in cell cycle progression [87].
Cyclin E is also involved in non-cell cycle related functions. Cyclin E/CDK2
phosphorylates p220/NPAT which functions in histone biosynthesis in S-phase (Figure
3) [82]. Specifically, cells deficient of p220/NPAT arrest late in G1 and are unable to
progress to S-phase. Another substrate of cyclin E/CDK2 is EZH2. Cyclin E/CDK2
phosphorylates EZH2 on T350 to facilitate targeting to specific loci and promote EZH2
transcriptional repression by H3K27 tri-methtylation [87]. Lastly, cyclin E is involved in
the apoptotic response. Cyclin E/CDK2 phosphorylates FOXO1, a transcription factor
that controls expression of pro-apoptotic genes such as Fas and Bim [87]. Specifically,
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cyclin E/CDK2 phosphorylates FOXO1 on S249, thereby signaling its cytoplasmic
translocation. Since cyclin E performs many cell cycle dependent and independent
functions inside the cell, deregulation of any of these functions sets the stage for
genomic instability and oncogenic transformation.
1.3c. The role of cyclin E in cancer
One of the first studies examining the oncogenicity of cyclin E found that
overexpression of cyclin E in combination with constitutively active H-Ras in rat
embryonic fibroblasts (REFs) resulted in foci that had been malignantly transformed
[89]. The capability of cyclin E along with active H-Ras to transform REFs puts cyclin E
in a elite group of oncogenes whose members also include Myc, SV 40 T-antigen and
E1A [81]. Moreover, examination of human cyclin E in transgenic mice revealed that
lactating mammary glands contained regions of hyperplasia and over 10% of the cyclin
E transgenic mice developed mammary carcinomas [90]. Furthermore, in the cyclin E
null mouse, Geng et al. and colleagues found that cyclin E was absolutely required for
oncogenic transformation [57].
Many cancer types have been shown to overexpress cyclin E protein or
amplify its mRNA transcript by as much as 64 fold including glioblastoma, breast, lung,
cervical, endometrium, gastrointestinal tract, bladder, melanoma, liver, prostate,
testis/ovary, bone, lymphoma, leukemia, sarcomas and adrenocortical tumors (Table 3)
[75, 81, 91, 92]. However, cyclin E and its role in breast cancer has been extensively
studied [93-97]. For example, patients displaying high levels of cyclin E have a worse
outcome compared to patients with low levels of cyclin E and this was shown to be
irrespective of the proliferation index by Ki67 staining [97]. Moreover, Keyomarsi and
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colleagues analyzed cyclin E expression and survival in 395 women with stage I-IV
breast cancer and found that high expression of cyclin E was an independent predictor
of survival; stronger than hormone receptor status and lymph node involvement [98].
There are multiple mechanisms that lead to deregulation of cyclin E
expression. First, mutations in the signaling pathways that converge upon Rb increase
cyclin E levels through E2F activation and although not as common, 2-20% of
endometrial, ovarian, colorectal, breast and gastric cancers contain cyclin E gene
amplification that may lead to increased mRNA levels [81]. Furthermore, defects in
cyclin E degradation have also been shown to lead to cyclin E overexpression. For
example, mutations in Fbw7 have been found in endometrial, pancreatic and colon
cancers as well as several human cancer cell lines [81].
The consequences of cyclin E overexpression include genomic instability
and centrosome amplification. One of the first studies examining overexpression of
cyclin E and genomic instability showed that constitutive overexpression of cyclin E, but
not cyclin D1 or cyclin A in murine and human cancer cell lines caused genetic
instability, specifically, defects during chromosomal duplication and segregation [99].
Genetic instability mediated by cyclin E overexpression is often linked with prolonged
S-phase. During replication excess cyclin E may result in defects of MCM proteins
loading at the replication fork and stalled replication forks are vulnerable to breakage
[81]. Moreover, defects in the replication process may result in premature mitosis entry
and chromosomes that have not been properly replicated leading to inappropriate
pairing and segregation [81].
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Centrosome amplification is also a consequence of cyclin E overexpression.
Studies in Xenopus laevis confirmed the requirement of cyclin E/CDK2 in centrosome
duplication during S-phase as well as multiple studies from mammalian systems [100102]. Faithful chromosome segregation during mitosis requires the two centrosomes to
form at the spindle poles. Centrosome amplification results in a multipolar spindles and
vast chromosome segregation errors. In vitro studies have shown that cyclin E
overexpression with concomitant p53 loss resulted in centrosome amplification and
aneuploidy [103]. Therefore, deregulation of cyclin E causes multiple defects in the
genomic integrity of the cell leading to neoplastic formation.
1.4 LOW MOLECULAR WEIGHT CYCLIN E
1.4a Generation and function of low molecular weight cyclin E
In addition to cyclin E gene amplification and protein overexpression in human
cancers, cyclin E is post-translationally cleaved into low molecular weight isoforms
(LMW-E) that range in size from 33-45kDa, compared to the 50kDa full length form of
cyclin E (EL1) (Figure 4) [104]. LMW-E are generated from N-terminal elastase
cleavage of EL at amino acids Q40-E45 to form the first isoform, LMW-E (T1), or A69D70 to form the second isoform, LMW-E(T2) [104]. In all, there are six isoforms of
cyclin E either resulting from post-translational cleavage (EL3 and EL6), alternative
translational start sites (EL4) or phosphorylation events (EL2 and EL5) (Figure 4) [105].
LMW-E are present in multiple tumor types including breast, ovarian, colorectal
cancers and melanomas [92, 106-108]. For example, a prospective study of 340
breast cancer patients with stage I or II disease showed tumor-specific expression of
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LMW-E, while normal adjacent breast tissue showed only full-length cyclin E [109]. A
causal role for LMW-E mediating tumorigenesis came from two important studies.
First, generation of LMW-E transgenic mice display enhanced mammary tumor
formation and metastasis compared to EL transgenic mice [110]. Specifically, 27% (34
of 124) LMW-E transgenic mice developed mammary tumors compared to 10.4% (7 of
67) EL transgenic mice [110]. Moreover, 25% of tumors from LMW-E transgenic mice
presented lung metastasis compared to 8.3% of tumors from EL transgenic mice [110].
Additionally, expression of LMW-E in non-tumorigenic human mammary epithelial cells
(hMECs) implanted into mice formed tumors in 74% (23 of 31) of animals, while only
7% (1 of 15) of mice formed tumors when implanted with EL expressing hMECs and
LMW-E tumorigenicity was further enhanced by in vivo passaging [111].
LMW-E have significant biological effects with respect to the tumorigenic
process. One function of the LMW-E isoforms is the deregulation of the G1/S transition
[112]. Specifically, expression of LMW-E in 76NE6 cells (non-tumorigenic human
mammary epithelial cells that have been immortalized by transfection of the 16E6 gene
of HPV) display a shortened G1 phase paired with a 2-fold increase in time spent in Sphase compared to EL or vector expression [112]. Additionally, these cells exhibit a
decreased doubling time, 28.3 to 31.1 hours for LMW-E expressing cells and 35.9-45.2
hours for EL and vector expressing cells [112].
Moreover, LMW-E are biologically hyperactive. It has been shown that LMWE/CDK2 complexes have increased kinase activity; more than EL/CDK2 complexes
and efficiently phosphorylate common cyclin E substrates such as histone H1 and Rb
[112-114]. Of note, LMW-E bind as efficiently to CDK2, p21 and p27 as EL and the
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increased kinase activity observed is not due to increased binding to CDK2 and/or
decreased binding to the CKIs [109, 112-114].
Overexpression of LMW-E also causes resistance to anti-estrogens.
Specifically, estrogen positive MCF7 cells overexpressing either EL or LMW-E have a
significantly greater percentage of cells in S-phase after treatment with the pure antiestrogen, ICI 182,780 [113]. While vector control cells displayed only 10% of cells in Sphase after anti-estrogen treatment, EL and LMW-E cells displayed 31% for EL, 40%
for LMW-E(T1) and 48% for LMW-E(T2) of cells in S-phase after treatment [113].
One of the mechanisms by which LMW-E mediates tumorigenesis is through
genomic instability. LMW-E overexpressing breast cancer cells have more polyploidy
and chromosomal aberrations such as chromosomal fragments, chromosomal breaks,
chromosomal fusions and subtelomeric chromatid breaks [109, 113]. The presence of
polyploidy is not only found in vitro, but in vivo as well. Analysis of 331 stage I-III
breast cancer patients show a significant correlation between cyclin E levels and
polyploidy [113]. Specifically, patients with high levels of cyclin E and polyploidy have a
lower 5-year DSS (Disease Specific Survival) than breast cancer patients with diploid
tumors [113].
LMW-E mediated chromosomal abnormalities are due to multiple defects during
mitosis. First, LMW-E overexpression leads to centrosome amplification [115]. Using
an inducible model system, Bagheri-Yarmand et. al and colleagues found that inducible
expression of LMW-E lead to a 2.5-fold increase in cells presenting more than two
centrosomes [115]. Additionally, these cells display defective spindle formation and a
number of other mitotic errors such as micronuclei, chromosome missegregation,
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anaphase bridges and cytokinesis failure [115]. These mitotic abnormalities were
found to be the result of deregulation of Cdc25C by cyclin E/CDK2 [116].
Another characteristic of LMW-E expression is the acquisition of a cancer stem
cell (CSC) phenotype along with the ability to undergo epithelial-to-mesenchymal
transition (EMT) [117]. LMW-E expressing hMECs, especially ones that have
undergone in vivo passaging also known as TDCs (tumor derived cells), activate an
EMT associated gene expression profile [117]. Epithelial genes such as E-cadherin
were decreased, while mesenchymal associated genes such as Vimentin, N-cadherin,
Twist and Slug all increased expression compared to EL expressing hMECs [117].
Additionally, LMW-E expressing hMECs and TDCs exhibited significantly higher levels
of CD44+/high/CD24-/low expressing cells, a characteristic marker of CSCs [117].
Interestingly, the CSC population in LMW-E expressing cells is mediated, at least in
part, by a histone acetyltransferase, Hbo1. Specifically, stable knockdown of Hbo1 in
cyclin E expressing hMECs significantly reduced the CSC population [117].
1.4b Low molecular weight cyclin E subcellular localization
Cyclin E has a classical nuclear localization sequence (NLS) that targets it to the
nucleus via the well characterized importin-α/importin-β import pathway [118].
However, the NLS in the LMW-E isoforms is lost post-translationally due to proteolytic
processing by elastase [104]. To examine the subcellular localization of LMW-E, Delk
et.al and colleagues first analyzed multiple immortalized mammary epithelial cell lines
as well as cancer cell lines of the breast, ovary and osteosarcoma [119]. Fractionation
of whole cell lysates followed by western blot analysis for cyclin E expression revealed
cytoplasmic localization of the LMW-E isoforms. Furthermore, to examine whether
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LMW-E/CDK2 complexes localized to the cytoplasm, green fluorescent protein (GFP)
was rationally bisected and each half was either fused to the cyclin E isoforms or
CDK2. In concordance with the western blot results, LMW-E/CDK2 complexes
preferentially localized to the cytoplasm, while EL/CDK2 complexes were found in the
nucleus of 98% of cells examined [119]. Interestingly, while in the cytoplasm, LMWE/CDK2 complexes were less sensitive to Fbw7 mediated degradation [119] .
Cytoplasmic localization of the LMW-E isoforms is correlated to cyclin E
biological deregulation. For example, the LMW-E isoforms are linked to cells with
centrosome abnormalities. Specifically, in 30 invasive breast carcinoma tissue
samples, those that present high levels of cytoplasmic LMW-E also show increased
levels of abnormal centrosomes with an r2=0.35 [115]. Moreover, in 118 breast cancer
patient tissue samples, patients with cytoplasmic LMW-E expression also display a
significantly increased population of CD44+/high/CD24-/low cells [117]. Together, these
findings indicate that the LMW-E isoforms are biologically and spatially different from
their full-length counterpart and their deregulation implies a functional role in the
tumorigenic process.
1.5 GAP IN KNOWLEDGE
Deregulation of cyclin E, especially the LMW-E isoforms, leads to molecular
events that are correlated with the tumorigenic process. Moreover, LMW-E expression
in women with stage I-III breast cancer is an independent predictor of survival.
However, understanding the mechanisms by which LMW-E predisposes the mammary
gland to tumorigenesis is still required and the following questions remain:
•
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•

Are the function(s) of the LMW-E cytoplasmic binding partner(s) enhanced
and/or suppressed?

•

Are cytoplasmic LMW-E binding partners required for LMW-E mediated
transformation, invasive capabilities and tumor growth?

These are the primary objectives of this dissertation and the following chapters include
research data to answer these questions. The overall hypothesis of this work is that
aberrant localization of the LMW-E isoforms leads to molecular interactions that
ultimately contribute to LMW-E breast cancer tumorigenicity. This dissertation
and future studies will continue to expose tumor-specific signaling pathways in breast
cancer that will help define appropriate treatment strategies and enable targeted drug
design for cancer therapies.
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CHAPTER 2: RETROVIRUS-BASED PROTEIN COMPLEMENTATION ASSAY
(REPCA) REVEALS NOVEL LMW-E BINDING PROTEINS
2.1 INTRODUCTION
2.1a. Methods used to identify protein-protein interactions
	
  

The study of proteomics involves an understanding how protein

structures, modifications, localization and interactions with other proteins affect how the
cell functions [120]. Two categories of proteomics research dominate the field,
expression proteomics and functional proteomics. Expression proteomics evaluates
changes in protein expression from normal cells under different conditions such as
exposure to drugs or disease state [121]. Functional proteomics, however, strives to
understand protein function and evaluate their role within the cell [121].
One of the most informative methods to understand protein function is through
identification of protein-protein interactions. Protein-protein interactions, either
transient or stable, are essential for every biological process including building enzymesubstrate complexes for signal transduction pathways, mediating ion channels, and
constructing the machinery for the cellular cytoskeleton [122]. One method to identify
protein-protein interactions is through affinity purification of proteins coupled to mass
spectrometry (AP-MS) (Table 4) [121, 123]. Specifically, the protein of interest is
tagged with peptides such as hemagglutinin (HA), FLAG, TAP (consisting of a
calmodulin-binding domain, a protease cleavage site, TEV, and a protein A tag) or
glutathione-S-transferase (GST) and purified from the protein mixture by an
immobilized solid support specific to the tag and/or by an antibody [121]. After binding,
the protein complex is then eluted, digested into small peptides and identified by mass
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Table 4: Common methods for identifying protein-protein interactions
High
Method
Abbreviation
Advantages
Disadvantages
through-put
capacity
Affinity
purification
followed by
mass
spectroscopy
or
Co-immunoprecipitation

AP-MS
or
Co-IP

•
•

Specific
Simple and
cost effective

•

Time efficient
• Cost effective
•

Yeast 2
hybrid

Split ubiquitin
system

•

Y2H

•
•

•

•

SUS

Suitable to
identify
membrane
proteins

•
•

•

Fluorescence
resonance
energy
transfer

•
FRET

•

•

	
  

Live cell
imaging
Quantitative
measurement
between
molecules
Localization
of protein
complexes
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•

•
•
•

Limited to more
stable
interactions and
high abundance
proteins
Tag interference

High false
positive rate
Dependent on
subcellular
localization
Interactions
dependent on
post-translational
modifications not
present in yeast
Time consuming
cloning
Protein structure
must be taken
into
consideration
False positive
readout due to
unknown
protease
cleavage of Cub
Insufficient on its
own to prove
protein complex
formation
Photo-bleaching
Expensive
equipment
Autofluorescence of
cells

yes

yes

yes

no

Bimolecular
fluorescence
or
protein
complementation
assays
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•
•

Live cell
imaging
Localization
of protein
complex
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•

•

Non-biological
levels of protein
and tag
interference
Expensive
equipment

no

spectroscopy; which measures the abundance of the peptides in the sample and the
mass-to-charge ratio [121]. AP-MS is amendable for high-throughput methods and has
high specificity, however, screening is often limited by subcellular localization and is
ineffective at isolating low copy number proteins or transient interactions [124, 125].
Furthermore, the tag added to the protein of interest may affect protein structure and
thus, limit protein interactions; but the use of smaller tags and varying the location of
the tag between the N- and C- terminal ends of the protein may alleviate this issue
[121].
Another method used to identify protein-protein interactions, though less
common, is a yeast two-hybrid (Y2H) assay and was developed in 1989 by Stanley
Fields and Ok-Kyu Song to confirm the interaction between two known interacting
proteins in yeast; SNF1 and SNF4 [126]. The premise behind the Y2H assay relies on
the activation of a downstream reporter gene by a transcription factor binding to an
upstream activation sequence (Table 4) (Figure 5) [127, 128]. Essentially, the protein
of interest or bait ‘X’ is fused to the DNA-binding domain (DBD), usually GAL4 or LEXA.
Then a cDNA library of prey proteins ‘Y’ are fused to the transcriptional activation
domain (TAD), usually GAL4 or B42 (Figure 5) [122]. The binding of ‘X’ to ‘Y’
reconstitutes a functional transcription factor and activates transcription of the reporter
gene in the nucleus [122, 127]. The Y2H assay is an attractive system to study proteinprotein interactions because it is time efficient and relatively inexpensive, however, the
Y2H assay has several limitations [129]. First, screening from a Y2H assay results in a
high false positive rate and is dependent on nuclear subcellular localization [125, 126].
The high false positive rate due to spontaneous transcriptional activation has been
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Figure 5. Schematic of the yeast-2-hybrid assay
The yeast-2-hybrid assay is a high-throughput method that is able to identify proteinprotein interactions in the nucleus. Activation of a reporter gene occurs when the bait
protein; which is fused to the DNA binding domain (DBD) of either GAL4 or LEXA,
binds to the prey protein; which is fused to the transcriptional activation domain (TAD)
of either GAL4 or B42. (Figure adapted from: Wodak, S.J., J. Vlasblom, A.L. Turinsky,
and S. Pu, Protein-protein interaction networks: the puzzling riches. Curr Opin Struct
Biol, 2013. 23(6): p. 941-53.
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reported when some proteins are fused to the DNA-binding domain without activation
by the interaction partner [130]. Moreover, protein interactions dependent on posttranslational modifications not present in the yeast system will be left unidentified [127].
The split ubiquitin system (SUS) is similar to the Y2H assay in that upon
protein interaction the reporter protein becomes functional (Table 4) [131]. The SUS,
as the name implies, utilizes a rationally bisected ubiquitin molecule: the N-terminal
half (Nub) and the C-terminal half (Cub) [122, 131]. Nub is fused to protein ‘X’ and Cub
is fused to protein ‘Y’ along with a transcription factor, PLV. Upon interaction of protein
‘X’ and protein ‘Y’ the ubiquitin molecule is reconstituted and ubiquitin-specific
proteases cleave the fused proteins from the ubiquitin molecule thereby liberating PLV
to act on target genes in the nucleus (Figure 6) [122, 131]. Recently, SUS was used to
identify NCX1; a novel interacting protein of Anoctamin6 (Ano6), required for bone
calcification [132]. The major advantage to SUS is that it is able to identify interactions
between membrane proteins. However, cloning membrane protein ORFs in E. Coli
often results in toxicity, but can be circumvented by cloning directly into yeast or using
specialized E. Coli expression vectors [122]. Additionally, SUS is susceptible to false
positive readouts due to cleavage of Cub by unknown proteases [122].
A fluorescence-based technique to identify protein-protein interactions is
fluorescence resonance energy transfer (FRET) [122]. Essentially, protein ‘X’ and
protein ‘Y’ are fused to a fluorescent donor and fluorescent acceptor, respectively, and
excitation of the donor results in energy transfer to the acceptor leading to dipole-dipole
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Figure 6. Schematic of the split ubiquitin system
The split ubiquitin system relies on the reconstitution of a rationally bisected ubiquitin
molecule, when reconstituted, activates transcription through the cleavage and
liberation of PLV into the nucleus. Specifically, the bait protein is fused to C-terminal
half of ubiquitin (Cub) and the prey protein is fused to the N-terminal half of ubiquitin
(Nub). Upon interaction of bait and prey proteins, Nub and Cub bind and reconstitute a
full ubiquitin molecule and liberates transcription factor PLV to act on target genes in
the nucleus. (Figure adapted from: Wodak, S.J., J. Vlasblom, A.L. Turinsky, and S. Pu,
Protein-protein interaction networks: the puzzling riches. Curr Opin Struct Biol, 2013.
23(6): p. 941-53.
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coupling [133]. FRET was recently used to identify a sumoylation modification by
SUMO2 on p35; which alters CDK5 activity under oxidative stress conditions in
neurons [134]. The energy transfer, E, can be quantitatively measured by the energy
absorbed by the donor and energy emitted by the acceptor. FRET is often described
as a molecular measuring tool due to a measuring range of 1-10nm, the distance of
molecules during protein complex formation, however, FRET is insufficient on its own
to prove protein-protein interactions and other methods are required [122].
Additionally, FRET is subject to false signals due to autofluorescence of cells or reabsorption of emission by donor [122].
Bimolecular fluorescence (BiF), also known as protein complementation
assay (PCA), is another method used to identify protein-protein interactions, but is also
used mainly to validate protein-protein interactions [122]. Similar to previous methods
described, a fluorescent reporter protein, such as GFP, is split into N- and C- terminal
fragments and each half is fused to one of the proteins of interest [135]. The
interaction between the proteins brings the two halves of the reporter protein together
reconstituting fluorescence [135]. This method is a powerful tool to analyze localization
of protein complexes and visualize protein-protein interactions in vivo, but similar to APMS, the size and localization of the reporter protein may result in binding interference
[122].
2.1b Retrovirus-based protein complementation assay
The Retrovirus-based protein complementation assay (RePCA) is a high
throughput method first utilized to identify protein-binding partners of Akt [125]. Using
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RePCA, Ding et al. and colleagues found 24 protein-binding partners of Akt; one of
which is ACTN4. ACTN4 was found to mediate Akt translocation to the membrane and
effect cellular proliferation [125].
RePCA combines PCA strategies with enhanced retroviral mutagenesis. The
enhanced retroviral mutagen (ERM) vector is superior to other retroviral-mutagenesis
techniques due to its high efficiency rate, ability to infect all mammalian cell types and
its available three ORFs to achieve in-frame integration sequences [136]. Furthermore,
the ERM vector provides efficient and regulated mutagenesis through several
engineered sequences. These sequences include a splice donor (SD) site and a
mutagenesis tag controlled by a tetracycline-responsive promoter, enabling the system
to be completely inducible [125].
As shown in Figure 7 the RePCA vector contains a tetracyclineresponsive promoter controlling the C-terminal half of intensely fluorescent protein
(IFPC) adjacent to the splice donor site. This SD site uses the endogenous splice
acceptor (SA) site within the host to generate in-frame fusions. For our purposes, since
Tet-on MCF7 cells were already established [137], we fused LMW-E(T1)- N-terminal
half to intensely fluorescent protein (IFPN) and transduced with the RePCA vector.
Upon induction with doxycycline, fluorescent cells, indicative of an LMW-E(T1)/Protein
‘X’ interaction, are sorted by fluorescence-activated cell sorting (FACS) to obtain clones
from a single cell. Fluorescent cells are expanded and Protein ‘X’ is identified by RNA
extraction followed by rt-PCR using primers specific to the RePCA vector. Finally, the
PCR product is gel purified, sequenced, and identified using a Genbank blast.
RePCA has a numerous advantages and are summarized in Table 5. First,
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Figure 7. Schematic of RePCA screen.
(A) Creation of RePCA retrovirus. The RePCA vector contains a tetracycline
responsive promoter, IFPC sequence and splice donor site. RePCA retrovirus is made
in packaging cells. Inside the host genome, the RePCA vector integrates to generate
IFPC-tagged “Protein X” fusions. (B) Flow chart of the RePCA screen. Stable LMW
E(T1)-IFPN expressing cells were generated in a tet-on MCF7 background and infected
with RePCA retrovirus. LMW-E(T1)/ “Protein X” interaction reconstitute fluorescence.
Single fluorescent cells were sorted by FACS and “Protein X” is identified by RNA
extraction from the fluorescent clone, followed by rt-PCR, sequencing, and a Genbank
blast. (Figure adapted from: Ding, Z., J. Liang, Y. Lu, Q. Yu, Z. Songyang, S.Y. Lin, and
G.B. Mills, A retrovirus-based protein complementation assay screen reveals functional
AKT1-binding partners. Proc Natl Acad Sci U S A, 2006. 103(41): p. 15014-9).
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Table 5: Advantages and disadvantages of RePCA
Advantages
• In vivo high-throughput screening
allows for native protein folding and
post-translational modifications
• Does not require generation of cellline specific cDNA libraries
• Context-dependent interactions
such as drug treatment or genetic
manipulation
• Employs endogenous splicing
machinery generating full length or
near-full length transcripts
• Inducible system
• Limited background fluorescence
when the PCA fusion proteins
interact
• Visualization of localization of the
protein complex
• The reconstituted IFP molecule is
highly stable and enables transient
interactions to be identified
• Membrane interactions are easily
identified
• Molecular interactions are directly
identified

•
•
•
•

Disadvantages
The ERM vector cannot capture
intron-less genes
Genes only available for virus
integration are targeted
Fluorescent tag may interfere with
some protein interactions
False positive interactions may be
identified

Adapted from:
Ding, Z., J. Liang, Y. Lu, Q. Yu, Z. Songyang, S.Y. Lin, and G.B. Mills, A retrovirus-based protein
complementation assay screen reveals functional AKT1-binding partners. Proc Natl Acad Sci U S A,
2006. 103(41): p. 15014-9.
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RePCA is performed in an endogenous environment and permits native protein folding
and post-translational modifications [125]. RePCA is amendable to any cell
type and generates full length or near-full length fusion transcripts due to the retroviral
vector integrating at or near transcriptional start sites [125]. Furthermore, the RePCA
vector contains a Tet-responsive promoter, which allows for inducible expression of
target genes. Finally, RePCA is powerful enough to identify transient interactions such
as enzyme-substrate interactions and can stabilize low affinity interactions [125].
Although RePCA has many advantages, there are disadvantages to
RePCA technology as well. Similar to AP-MS, the fluorescent tag may inhibit the
formation of select protein-protein interactions (Table 5). Also, intron-less genes, which
comprise 3% of the human genome, are unable to be discovered by RePCA [125, 138].
Nevertheless, RePCA is a suitable method to identify a wide range of protein-protein
interactions in any subcellular compartment that might otherwise go undiscovered by
classical methods.
2.1c Hypothesis and specific aims
LMW-E are void of an NLS and thus, LMW-E/Cdk2 complexes accumulate in the
cytoplasm with reduced levels in the nucleus [119]. Therefore, we hypothesize that
aberrant localization of tumor-specific LMW-E in the cytoplasm leads to
oncogenic protein interactions ultimately contributing to LMW-E tumorigenicity
in breast cancer.
The hypothesis will be addressed with the following specific aims:
•

Generate Tet-on MCF7 cells stably expressing EL-IFPN, T1-IFPN and T2-IFPN
fusion proteins.
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•

Identify LMW-E(T1) binding proteins in the cytoplasm utilizing the retrovirusbased protein complementation assay.

•

Validate novel interactions by co-immunoprecipitation.

Briefly, results presented in this chapter reveal 11 novel interacting proteins of
LMW-E(T1). The proteins identified range in function from metabolism and signal
transduction to protein trafficking and stress response. Among the novel LMW-E(T1)
interacting proteins identified, ATP-citrate lyase, the primary enzyme responsible for
synthesis of acetyl-CoA and oxaloacetate in the cytoplasm, is a novel discovery
implicating a possible link between the cell cycle machinery and cellular metabolism in
breast cancer.

2.2 MATERIALS AND METHODS
2.2a. Cell culture and constructs
Breast cancer MCF7 Tet-On cells were purchased from BD Clontech (Palo Alto,
CA) and cultured as previously described [139]. The LMW-E (T1) intensely fluorescent
protein N terminus (IFPN) construct was generated previously [119] and used to create
MCF7 Tet-On cells stably expressing the LMW-E (T1)-IFPN construct by selection with
80 µg/mL zeocin (Invitrogen, Grand Island, NY). Embryonic kidney HEK 293T/17 cells
from ATCC (Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS and used to produce retrovirus. Retroviral RePCA
plasmids IC1, IC2 and IC3 and packaging plasmids pcGP and pVSVG were a kind gift
from Gordon Mills (The University of Texas MD Anderson Cancer Center).
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2.2b. Retrovirus-based protein complementation assay
RePCA was performed as previously described [125]. Briefly, IC1, IC2 or IC3
retrovirus was produced in HEK 293T/17 cells and subsequently used to transduce a
total of 10 x 106 MCF7 Tet-On cells stably expressing the LMW-E (T1)-IFPN construct
on 6-well p150 plates. Infected cells were grown for 1 week with 2 µg/mL puromycin
(Invitrogen). Puromycin-resistant cells were subjected to fluorescence-activated cell
sorting for green fluorescent protein (GFP) expression using a BD FACSAria II cell
sorter (BD Biosciences, San Jose, CA). Single cells were grown at a very low density
in minimal essential medium α containing 2 µg/mL puromycin to form clones. The
clones were expanded, and RNA was extracted using RNAeasy mini kits (Qiagen,
Valencia, CA). Reverse transcription was performed with a random primer (RT-1) as
previously described using a Transcriptor First Strand cDNA synthesis kit (Roche,
Indianapolis, IN). A T7 primer sequence is embedded within the 5’ end of the RT-1
primer. The cDNA was amplified by PCR with an intensely fluorescent protein C
terminus (IFPC)-specific primer and a T7 primer using HotStarTaq DNA polymerase
(Qiagen). PCR products were gel purified using a QIAEX II gel extraction kit (Qiagen)
and sequenced at the Sequencing and Microarray Facility at the MD Anderson Cancer
Center. Sequences were identified using GenBank BLAST.
2.2c Immunocytochemical analysis
RePCA clones were cultured on coverslips in the presence of 2 µg/mL
doxycycline for 48 hours. The cells were then fixed with 4% paraformaldehyde, and
nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (Sigma, St. Louis,
MO).
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2.2d Cell lysis, immunoblotting, and co-immunoprecipitation
Cell lysates were prepared and subjected to Western blot analysis as previously
described [139]. Western blots were incubated with primary antibodies against Flag
M2, Flag produced in rabbit (Sigma), myc-Tag 9B11, glutathione S-transferase (GST),
ACLY (Cell Signaling, Danvers, MA), cyclin E HE12, Cdk2 (Santa Cruz Biotechnology,
Dallas, TX). All antibodies were used according to the manufacturer’s instructions.
The blots were washed and probed with horseradish peroxidase-labeled secondary
antibody and detected using enhanced chemiluminescence. Co-immunoprecipitation
was performed with anti-Flag M2 antibody in lysis buffer (50 mM Tris [pH7.5], 250 mM
NaCl, 0.1% NP40, and a protease inhibitor cocktail). The protein/antibody mixture was
incubated with Protein G Sepharose 4 Fast Flow (GE Healthcare, Pittsburg, PA) at 4°C
overnight. Beads were washed four times with lysis buffer without protease inhibitors
and subjected to SDS-PAGE.
2.2e GST pull-down, GST-ACLY protein truncations and kinase assay
GST-ACLY fusion protein and GST-ACLY protein truncations were constructed
using the Gateway cloning method from Invitrogen. Recombinant GST-ACLY fusion
protein was expressed in Escherichia coli BL-21 cells and induced with 0.5 mM
Isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were lysed in NETN buffer (150
mM NaCl, 1 mM EDTA, 20 mM Tris [pH8.0], and 0.5% NP-40) plus 1 mM
phenylmethylsulfonyl fluoride (PMSF), 1 mM DL-dithiothreitol (DTT), 50 µg/mL
lysozyme, and protease inhibitors. GST-ACLY fusion protein was purified using
Glutathione Sepharose 4B beads from GE Healthcare. In vitro transcription and
translation of cyclin E isoforms and Cdk2 were performed using the TNT-coupled
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reticulocyte lysate system (Promega, Madison, WI), and these proteins were added to
the mixture of GST-ACLY and glutathione beads. Purified SFB-cyclin E isoforms were
expressed in 293T cells and isolated using Flag M2 antibody (Sigma) and subsequently
eluted using Flag M2 peptide from Sigma. For the GST-ACLY kinase assay, lysates
from Sf9 cells expressing either EL, T1 or in combination with CDK2 were
immunoprecipitated using CDK2 antibody. GST-ACLY aa426-486 were incubated with
Sf9 immunoprecipiates or purified AKT1 (Millipore, Billerica, MA) in kinase buffer
containing 60 µM cold ATP and 5 µCi [32P] ATP to a final volume of 30 µl at 37°C for 30
min. The products of the reactions were then analyzed on a 7% SDS-PAGE gel. The
gel was then stained, destained, dried, and exposed to X-ray film.

2.3 RESULTS
2.3a. RePCA reveals novel LMW-E(T1) binding proteins
To identify LMW-E(T1) binding proteins in the cytoplasm we utilized RePCA
technology. We first created Tet-on MCF7 cells that stably express EL-, T1- or T2IFPN vectors and picked clones for expression. We obtained correct expression from
both T1- and T2-IFPN clones, however, EL-IFPN clones showed expression at a
reduced molecular weight and were not used as part of the screen (Figure 8A). The
second step of RePCA is infection of the host cell line with the RePCA retrovirus. We
chose to infect LMW-E(T1)-IFPN clone 5, due to its high expression, with all three
ORFs of the RePCA retrovirus. After one week of 2 µg/mL puromycin selection, the
infected cell population was subjected to fluorescence activated cell sorting (FACS) to
isolate fluorescent cells that are indicative of an LMW-E(T1)/Protein ‘X’ interaction. For
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Figure 8. RePCA screening process for LMW-E(T1) interacting proteins
(A) Identification of IFPN clones. EL-IFPN, T1-IFPN and T2-IFPN clone lysates were
subjected to western blot analysis for cyclin E expression using cyclin E antibodies.
(B) IC1 RePCA infected cells were sorted and fluorescent cells were isolated. (C) RNA
from IC1 sorted clones were analyzed on an agarose gel. (D) PCR products were
analyzed on an agarose gel to examine size of LMW-E(T1) interacting partners.
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example, from 10 x 106 cells infected with IC1 RePCA retrovirus, we isolated 0.8%
(approximately 80,000 single cells) fluorescent cells (Figure 8B). The 80,000 cells
were plated at a very low density and we obtained 204 colonies that were further
isolated and transferred to a 12-well plate. Upon induction of doxycycline, 61 of the
204 (29.9%) colonies retained fluorescence and were further expanded. Next, we
extracted RNA from the expanded clones (Figure 8C) and analyzed this for purity or
degradation. Lastly, we reverse-transcribed the RNA and amplified the RePCA region
of interest by PCR using primers located within the RePCA vector. The PCR products
were gel purified (Figure 8D) and sequenced.
We identified 11 independent LMW-E (T1)–binding proteins in MCF7 cells
(Table 6). The IFPC fusion transcript integrated at or near the transcriptional start site
in 6 of the 11 transcripts, indicating that full-length or near-full-length proteins were
generated. We found that the majority of the interacting proteins identified (8 of 11,
73%) were known to be localized to the cytoplasm (Table 6). YWHAQ (14-3-3β)
mediates protein signaling by binding to phosphoserine-containing proteins [140].
HSP27 (heat shock protein 27) is a chaperone protein induced upon environmental
stress [141]. HSP90 (heatshock protein 90), another chaperone protein, facilitates
proper protein folding and protects against promiscuous protein-protein interactions
[142]. VAMP8 (vesicle-associated membrane protein 8) is a component of a complex
of proteins involved in the docking of synaptic vesicles with the presynaptic membrane
[143]. COG4 (component of oligomeric golgi complex 4) is involved with protein
trafficking at the Golgi apparatus [144]. RPL41 (ribosomal protein L41) is a component
of the 60S subunit of the ribosome and important for mitosis and centrosome integrity
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Table 6: Interacting proteins of LMW-E (T1) identified from RePCA
Amino
acid
insertion
site

Protein
name

Protein
symbol

trans-2,3-enoylCoA reductase

TECR

Fatty acid
synthesis

IC1

+4

Endoplasmic
reticulum

Aldolase-A

ALDO-A

Glycolysis

IC1

-7

Cytoplasm

ATP-citrate lyase

ACLY

Fatty acid
synthesis

IC1

-8

Cytoplasm;
nucleus

YWHAB

Signaling

IC1

-4

Cytoplasm

Heat shock
protein 27

HSP27

Stress
Response

IC1

-37

Cytoplasm;
nucleus

Heat shock
protein 90

HSP90

Stabilization

IC1

+1

Cytoplasm

Vesicle-associated
membrane protein 8

VAMP8

Protein
docking

IC1

+57

Plasma
membrane

Component of
oligomeric
complex 4

COG4

Transport

IC2

+649

Golgi
apparatus

RANBP1

Transport

IC1

+5

Cytoplasm;
nucleus

RPL41

Protein
synthesis

IC2

+11

Cytoplasm

eIF3J

Protein
synthesis

IC1

+49

Cytoplasm

Tyrosine 3monooxygenase/
tryptophan 5monooxygenase
activation protein,
beta
polypeptide

RAN binding
protein 1
Ribosomal
protein L41
Eukaryotic
translation initiation
factor, subunit J
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Known
localization

[145]. RANBP1 is a GTPase that facilitates protein transport across the nuclear
membrane [146]. Eukaryotic translation initiation factor 3J (eIF3J) is the 13th subunit of
the eIF3 complex and aids in the initiation of transcription [147]. The three remaining
novel interacting proteins of LMW-E (T1) identified constituted the largest functional
group (3 of 11, 27%) of proteins discovered from the screen; these proteins are
involved in metabolism. trans-2,3-enoyl-CoA reductase (TECR) catalyzes the final step
in synthesizing long and very long chain fatty acids [148]. Aldolase A (ALDO-A), also
known as fructose-bisphosphate, plays a key role in glycolysis and gluconeogenesis
[149]. ACLY, catalyzes the first step of the de novo lipogenesis pathway and converts
cytoplasmic citrate to acetyl-CoA and oxaloacetate [150]. The end products of this
lipogenesis pathway are fatty acids and other metabolic intermediates needed by
proliferating cells [151]. Elevated ACLY protein and activity levels correlate with tumor
growth and progression in breast carcinoma, lung adenocarcinoma, and glioblastoma
[152-154], and ACLY inhibition by genetic or pharmacologic methods suppresses tumor
growth [155]. On the basis of its role in promoting tumor growth and its novel
interaction with cyclin E, we selected ACLY for further investigation.
2.3b. Cyclin E and ACLY are interacting proteins
To examine the localization of the LMW-E (T1) protein complexes, we subjected
several RePCA clones to fluorescence microscopy. The LMW-E(T1)/ACLY interaction
was identified in clones #18 and #46 (Figure 9A) and the LMW-E(T1)/ACLY complex
localized primarily to the cytoplasm. In another clone, #16, we identified a interaction
between LMW-E(T1) and VAMP8 (Figure 9A). This interaction localizes to the plasma
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Figure 9. Validation of RePCA clones.
(A) RePCA clone #46, #18 and #16 were fixed and counterstained with Dapi.
Fluorescence shows localization of the LMW-E (T1)/ Protein ‘X’ interaction. (B) 293T
cell lysates expressing SFB-tagged cyclin E isoforms and myc-ACLY were
immunoprecipitated using an anti-Flag antibody. (C) Recombinant GST-ACLY protein
was incubated with in vitro transcribed and translated (TnT) cyclin E isoforms or Cdk2
and isolated using Glutathione sepharose beads. (D) In vitro kinase assay using
recombinant GST-ACLY aa 426-486 and recombinant Cyclin E isoforms alone or in
complex with CDK2 were isolated by Cdk2 immunoprecipitation and incubated with
GST-ACLY in the presence of 32P-γ-ATP. The samples were run on an SDS-PAGE gel
and the autoradiography film is shown. Akt1 was used as a positive control.
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membrane. The LMW-E (T1)- ACLY interaction was confirmed by coimmunoprecipitation. Lysates expressing myc-ACLY and either EL- or T1- N-terminally
tagged with SFB (S-tag, Flag epitope tag, and streptavidin-binding peptide tag) showed
that both full-length EL and LMW-E (T1) were able to bind ACLY (Figure 9B).
Since Cdk2 is the primary binding partner of cyclin E, we examined whether
cyclin E or Cdk2 directly binds ACLY. A GST pull-down assay revealed cyclin E as the
direct binding partner of ACLY and the interaction is not mediated by other proteins
including CDK2 (Figure 9C). Furthermore, ACLY is phosphorylated post-translationally
by multiple proteins, including cAMP-dependent protein kinase, GSK3β, nucleoside
diphosphate kinase (NDPK) and protein kinase B (Akt) [156-158]. Therefore, we
examined whether ACLY is a substrate of the cyclin E/Cdk2 complex. An in vitro
kinase assay revealed that ACLY is not a substrate of EL/Cdk2 or T1/Cdk2. Akt1,
known to phosphorylate was used as a positive control [153]. Together, these results
indicate that ACLY directly binds cyclin E and protein binding does not result in
phosphorylation of ACLY.
2.3c. Identification of the ACLY domain that binds to cyclin E
ACLY, a member of the acyl-CoA synthetase (NDP-forming) superfamily [159],
is similar in structure to succinyl-CoA synthetase (SCS) and consists of five domains
shared by all members of this superfamily [160]. The domains are numbered
corresponding to their order in Escherichia coli SCS [161]. As shown in figure 10A
domain 1 binds CoA and domain 2 binds the catalytic phosphohistidine residue.
Together, domains 3 and 4 form an ATP grasp fold and bind nucleotide. Domain 5
binds domain 2, creating one of two “power helices”. The region of ACLY between 5
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Figure 10. Analysis of interaction between cyclin E and ACLY
(A) Schematic of ACLY protein. An N-terminal GST tag was added to ACLY protein.
ACLY consists of five domains followed by a citrate synthase homology domain
(adapted from [160]). Six truncations of GST-ACLY were generated to study the
interaction between cyclin E and ACLY. (B) Coomassie stained gel showing purification
of SFB-tagged cyclin E isoforms from HEK 293T cells. (C) Recombinant GST-ACLY
protein truncations were incubated with purified SFB-LMW-E(T2) and complex
formation was isolated using Glutathione sepharose beads. (D) SFB-LMW-E(T2) alone
or SFB-LMW-E(T2) + GST-ACLY WT were incubated in the presence of glutathione
beads and complex formation was assessed.
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and 1 is the highly phosphorylated region of the protein [160]. The C-terminal end of
ACLY displays high sequence homology to the large domain of citrate synthase [160].
To identify which region of ACLY interacts with cyclin E we generated six GST-ACLY
fusion protein truncations utilizing the Gateway cloning system and expressed these
recombinant proteins in E coli (Figure 10A). Additionally, we overexpressed SFBtagged isoforms of cyclin E in HEK 293T cells and purified the cyclin E complexes by
Flag pull-down and elution with Flag peptide (Figure 10B). Purification resulted in
isolation of all three isoforms of cyclin E.
We performed a GST pull-down assay using our purified cyclin E isoforms and
GST-ACLY protein truncations. Expression of GST-ACLY truncations was variable,
with aa 2-243, aa 244-425 and aa 426-624 showing very high expression, while GSTACLY WT was the least expressed, probably due to the size of the fusion protein (over
150kDa). Surprisingly, pull-down analysis showed that all truncations of ACLY bound
very effectively to LMW-E(T2) (Figure 10C). This result was also seen in the other
isoforms of cyclin E (EL and LMW-E(T1)) (data not shown) and was suspicious
because every truncation created should not be able to bind to cyclin E. Therefore, we
suspected non-specific binding could be due to something that each of the truncations
has in common, the SFB-tag or the glutathione beads. To examine non-specific
binding to the beads, we incubated SFB-T2 alone or in combination with the glutathione
beads and as suspected, SFB-T2 was able to bind without the requirement of the GST
tag (Figure 10D). In our hands, the use of GST and SFB tags on ACLY and LMWE(T2), respectively, did not result in identification of the region of binding and future
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studies will require creation of a different cyclin E fusion protein that minimizes nonspecific binding.

2.4 CONCLUSIONS
In the age of proteomics, methods to identify protein-protein interactions are
essential to understanding protein function. The methods to identify protein-protein
interactions have become increasingly more reliable by reducing false positive rates
and enhancing specificity. In this chapter we have shown that RePCA is an effective,
high throughput method to identify protein-protein interactions in an endogenous
environment. RePCA was first utilized to identify protein binding partners of Akt1 and
we confirm that RePCA is a useful tool to identify protein-protein interactions [125]. We
created a host cell line, MCF7, containing IFPN-tagged forms of cyclin E and
subsequently transduced LMW-E(T1) with the RePCA vector. From 10 x 106 cells
originally infected, we obtained 61 colonies from which to extract RNA. Of the 61
colonies, we identified 11 novel interacting proteins of LMW-E(T1) and most proteins
identified localized to the cytoplasm (Table 6). Ding and colleagues found 24
independent binding partners of Akt from all three RePCA ORFs [125]. Specifically,
from the IC2 ORF, 2 x 107 cells were infected and subsequently formed 384 colonies.
Furthermore, 14% of colonies retained fluorescence after doxycycline induction. These
results are similar to what we found using RePCA screening methodology in that
RePCA yields tens of candidates, not hundreds like AP-MS.
To validate our results from the RePCA screen, we first subjected several clones
to fluorescence microscopy to investigate subcellular localization of the LMW-E(T1)
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protein complex. The localization of the LMW-E(T1)/ACLY protein complex from
RePCA clones #46 and #18 were localized primarily to the cytoplasm with a small
percentage of cells showing nuclear localization (Figure 9A). Moreover, we confirmed
the interaction between LMW-E(T1) and ACLY by co-immunoprecipitation and
identified the interaction is direct and not mediated by other proteins (Figure 9B,C)
Regulation of ACLY, in part, occurs through multiple phosphorylation events
[156-158]. For example, an antibody raised against an Akt substrate consensus
sequence proved ACLY to be a substrate of Akt in rat primary adipocytes in an insulindependent manner [158]. Therefore, we investigated whether ACLY could be a
substrate of cyclin E/Cdk2 and our results revealed that cyclin E/Cdk2 does not
phosphorylate ACLY (Figure 9D).
To gain insight to function of the cyclin E/ACLY protein complex, we investigated
which domain of ACLY bound to cyclin E. We created six truncations of a GST-ACLY
fusion protein and created purified isoforms of cyclin E to examine binding (Figure
10A,B). However, our binding analysis revealed that our SFB-cyclin E fusion protein
was non-specifically binding to the glutathione beads, thus preventing the identification
of the region that binds to cyclin E (Figure 10D). Future experimental designs will avoid
SFB-tagged proteins and glutathione beads and will utilize other tags such as MBP
(maltose binding protein) for purification. Nevertheless, the use of RePCA technology
to identify LMW-E(T1) binding protein in the cytoplasm was successful and the
identification of ACLY as a cyclin E binding protein sheds new light on how the cell
cycle and cellular metabolism are coupled in breast cancer.
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CHAPTER 3: ATP-CITRATE LYASE LINKS LOW MOLECULAR WEIGHT CYCLIN E
TO CELLULAR METABOLISM IN BREAST CANCER

3.1 INTRODUCTION
3.1a. Overview of cancer cell metabolism
In 2000, Douglas Hanahan and Robert Weinberg published the seminal paper,
“The Hallmarks of Cancer” describing six characteristics of human cancers that allow
cancer cells to proliferate, survive and metastasize throughout the body [72]. These
characteristics include: growth signal self-sufficiency, insensitivity to antigrowth signals,
evasion of apoptosis, limitless replicative potential, maintained angiogenesis, and
tissue invasion and metastasis [72]. A decade later, they revised the hallmarks to
include emerging hallmarks of cancer such as deregulated cellular energetics and
evasion from immune destruction [162].
The idea that cancer cells display defects in metabolic regulation was first
described almost 100 years earlier by Otto Warburg [163]. Under normal conditions,
non-proliferating cells undergo aerobic respiration; a process in which glucose is
converted to pyruvate via glycolysis, then to carbon dioxide following oxidative
phosphorylation (OXPHOS) in the mitochondria yielding a net total of 36 ATP from one
glucose molecule [162, 164]. On the other hand, proliferating cells undergo anaerobic
respiration either when oxygen levels are limited or to meet the demands of
macromolecular synthesis (DNA, membrane or protein synthesis) and primarily utilizes
glycolysis for energy yielding a total of 2 ATP molecules [162]. However, many cancer
cells, even under conditions when oxygen is present, primarily exploit glycolysis for
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energy production; an event coined the ‘glycolytic switch’, ‘aerobic glycolysis’ or
‘Warburg effect’ [163, 165].
The Warburg effect, on its own, is a highly inefficient method to produce the
energy required to fuel a proliferating cell population and therefore, to keep up with
demand, the cancer cell increases glucose uptake which in turn results in lactate
excretion [165, 166]. The elevated level of glucose uptake by cancer cells is exploited
clinically through the use of [18F] fluorodeoxyglucose positron emission tomography
(FDG-PET) imaging [163, 165-167]. Specifically, FDG-PET uses a radiolabeled
glucose analogue to expose regions of high glucose consumption and has been shown
to be efficacious in diagnosing and monitoring tumors [165].
Ultimately, the metabolic reprogramming of cancer cells to aerobic glycolysis is
advantageous to fuel growth since aerobic glycolysis consumes glucose; one of the
most plentiful extracellular nutrients, and uses it for ATP production [165]. Additionally,
elevated influx of glucose provides the substrates required for macromolecular
biosynthetic pathways [165, 166]. For example, ribose sugars are used during
nucleotide synthesis, and citrate, from a truncated tricarboxylic acid cycle (TCA),
provides substrates required for fatty acids production, and nonessential amino acids
for protein production [166, 167].
3.1b. Deregulated metabolic pathways in cancer
The PI3K/Akt signaling pathway serves as a hub for multiple downstream
pathways required for cell survival, proliferation and protein synthesis (Figure 11) [168].
Consequently, this pathway is also one of the most frequently mutated pathways in
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Figure 11. Molecular pathways that induce the Warburg effect
The Warburg effect can be induced by oncogenic pathways to confer a glycolytic
phenotype. The PI3K/Akt/mTOR pathway enhances the glycolytic phenotype by
regulating enzymes directly involved in glycolysis or by activating key transcription
factors and can be negatively regulated by the AMPK pathway. p53 also plays an
important role in regulating the expression of key metabolic enzymes including HK2
and TIGAR as well as influencing PI3K pathway through inhibition of tumor suppressor,
PTEN. (Figure adapted from Cairns, R.A., I.S. Harris, and T.W. Mak, Regulation of
cancer cell metabolism. Nat Rev Cancer, 2011. 11(2): p. 85-95.)
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human cancer (Table 7) [165]. Mutations in the tumor suppressor, phosphatase and
tensin homolog (PTEN), mutations in the PI3K complex or inappropriate signaling from
receptor tyrosine kinases (RTKs) all confer a growth and survival phenotype in cancer
cells through constitutively activating Akt and promoting the Warburg effect through
multiple mechanisms [165]. First, Akt can facilitate glucose transporters such as
GLUT1, to translocate to the membrane to increase glucose uptake [165, 166, 169].
Additionally, Akt influences transcriptional changes that result in elevated glycolytic
function through inhibition of the forkhead box subfamily O (FOXO) family of
transcription factors [165, 170]. Lastly, Akt is responsible for promoting signaling
through mammalian target of rapamycin (mTOR) by inhibition of its negative regulator,
tuberous sclerosis 2 (TSC2) [165]. The mTOR pathway acts as a sensor of nutrient
availability and if growth conditions are sufficient, can promote protein synthesis,
specifically, mRNA translation and ribosome biogenesis [165, 171]. Furthermore, the
mTOR pathway in tumor cells can promote transcriptional changes through activation
and stabilization of hypoxia-inducible factor 1 alpha (HIF1α) even when oxygen
conditions are normal [165].
Another pathway often deregulated in cancer cells is the AMPK pathway (Figure
11). AMPK (AMP-activated protein kinase) acts a checkpoint for energy stress [165].
Under conditions of energy stress such as a low AMP/ATP ratio, AMPK becomes
activated and signals the cell to switch from glycolytic metabolism to oxidative
metabolism; thus, abrogating cellular proliferation [165, 172, 173]. Tumor cells are able
to bypass this checkpoint pathway by mutating the tumor suppressor, LKB1 (liver
kinase B1) (Table 7). LKB1 mutations are responsible for Peutz-Jeghers syndrome; a
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Table 7: Molecular alterations that affect metabolic circuits
Molecule

	
  

Activity in cancer

PI3K

Mutation; gain-of-function

PTEN

Mutation; loss-of-function

LKB1

Mutation; loss-of-function

HIF1α

Constitutive expression; gainof-function

Myc

Constitutive expression; gainof-function

Ras

Mutation; gain-of function

p53

Mutation; loss-of-function

VHL

Mutation; loss-of-function

PKM2

Alternative splice variant; lower
activity
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Consequence in
cancer

Refs

Activation of Akt and
facilitates
upregulation of
glucose transporters,
transcription factors
and mTOR
Activation of Akt and
facilitates
upregulation of
glucose transporters,
transcription factors
and mTOR
Increased glycolytic
flux; activation of
mTOR and HIF1α
Increases expression
of genes encoding
glycolytic enzymes,
VEGF and other
proteins involved in
the hypoxic response
Increases expression
of LDH-A; increases
glycolysis and lactate
production
Increases glycolysis
and VEGF
expression
Stabilized by HIF1α;
activates HK2;
induces apoptosis
under hypoxic and
acidic conditions
through TIGAR
expression
Destabilizes hypoxia
induced transcripts;
VEGF and GLUT1
Guides carbon
sources away from

165,
166,
169,
170

165

165,
173175
165,
166,
176

165

165
165,
179,
180

165,
177,
178
165,
182-

IDH1/2

SDH

FH

	
  

Mutation; loss-of-function; gainof-alternative function

Mutation; loss-of-function

Mutation; loss of function
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OXPHOS
Creates oncometabolite
Elevated levels of
succinate;
impairment of PHD3;
elevated levels of
HIF
Elevated levels of
fumarate;
modification of
cysteine residues
leading to negative
regulation of Nrf2;
upregulation of antioxidant response
genes

185
165,
190,
191
166,
192

166,
192

disease which starts out as benign lesions of the gastrointestinal tract and oral cavity,
but shifts to increase the risk of a wide range of other malignancies [165]. Moreover,
LKB1 is mutated in 15-35% of non-small cell lung cancer (NSCLC) cases and 20% of
cervical carcinomas [173-175]. Ultimately, loss of AMPK signaling can lead to
activation of mTOR and HIF1, both leading to an increased glycolytic phenotype [165].
HIF1α, as previously mentioned, can be induced through transcriptional
activation downstream of PI3K, Akt and mTOR (Figure 11) [165]. Under normal
oxygen conditions, HIF1α is posttranslationally modified by prolyl hydroxylation and this
modification signals von Hippel-Lindau (VHL) tumor suppressor, a ubiquitin ligase,
ultimately leading to HIF1α degradation [165, 166]. However, under hypoxic
conditions, HIF1α is stabilized and transcriptionally activated to increase expression of
glucose transporters and glycolytic enzymes [166, 176]. Of note, HIF1α can be
activated under normoxic conditions in tumor cells by the inactivation of VHL or
mutations in the PI3K pathway (Table 7) [165]. For example, in renal-cell carcinoma,
mutations in VHL lead to constitutively active HIF1α and re-expression of VHL is able
to rescue HIF1α function and decrease the aerobic glycolysis phenotype [177, 178].
Lastly, although primarily known for its essential role in regulating DNA damage
and the apoptosis response, p53 is also a player in regulating key metabolic genes
(Figure 11) [165]. First, p53 can induce the expression of HK2 (hexokinase 2), the first
enzyme in glycolysis and produces glucose-6-phosphate (Figure 11) (Table 7) [165,
179]. Glucose-6-phosphate is an important molecule and is present at the crossroads
of two metabolic pathways: glycolysis and the pentose phosphate pathway (PPP).
Glycolysis produces ATP and synthesizes pyruvate for the tricarboxylic acid cycle
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(TCA) and the PPP produces NADPH and ribose sugars, both important for nucleotide
synthesis [165]. Furthermore, p53 regulates expression of TIGAR (TP-53 induced
glycolysis and apoptosis regulator), an enzyme that controls the levels of a key
glycolysis enzyme, fructose-2,6-bisphosphate [165, 180]. Lastly, it is well known that
p53 is a regulator of PTEN, a key inhibitor of the PI3K pathway [165, 181].
3.1c. Onco-enzymes and onco-metabolites in metabolic pathways
Pyruvate kinase (PK) functions in the final irreversible step of glycolysis
converting phosphoenolpyruvate (PEP) to pyruvate (Figure 11) [165, 182]. In
mammals, there are multiple isoforms of PK including type L, type R, type M1 and type
M2 [165, 183]. Type L is expressed in the liver and kidney; type R is found in
erythrocytes; type M1 is expressed in the muscle cells and brain; and type M2 is found
in embryonic stem cells, adult stem cells and tumor cells [165, 183]. PK is found either
as an inactive monomer, low activity dimers or as active tetramers [182]. The low
activity dimer is what is most often found in many cancers and although
counterintuitive, its low enzymatic activity decreases the rate of glycolysis and thus,
increases metabolic flux required for macromolecular biosynthesis through PPP for
nucleotide synthesis and other pathways for phospholipid and amino acid synthesis
[165, 167, 183-185]. Indeed, expression of PKM2 in lung cancer cells is more
conducive to tumor growth than the PKM1 isoform [184].
The expression of PKM2 over PKM1 in cancer cells is due to preferential
expression by myc coupled with unique splicing events [165]. Specifically, myc induces
the expression of heterogeneous nuclear ribonucleoproteins (hnRNPs) that bind and
inhibit exon 9, which encodes PKM1 and liberates exon 10, which encodes PKM2 [165,

	
  

75	
  

186]. At the enzymatic level, negative regulation of PKM2 occurs by growth factorderived phosphotyrosine signaling by FGFR1, Bcr-Abl and JAK2 [187].
PKM2 is primarily a cytoplasmic enzyme, but has recently been shown to
localize to the nucleus as well [188]. This translocation is due to apoptotic signals,
response to IL-3, acetylation on Lys 433 or by phosphorylation by extracellular signalrelated kinase 2 (ERK2) [182]. Specifically, upon EGFR stimulation, ERK2 interacts
with and phosphorylates PKM2 at serine 37 [188]. This phosphorylation recruits PIN1
for cis-trans isomerization leading to exposure of its NLS and interaction with importin
5α [188, 189]. Nuclear PKM2 in concert with β-catenin induces myc expression,
eventually resulting in GLUT1 and LDH-A expression forming a positive feedback loop
[188, 189]. Ultimately, PKM2 expression in tumor cells has the ability to guide carbon
precursors away from pyruvate production and into pathways responsible for
macromolecular biosynthesis required for growth and proliferation.
Additional onco-enzymes are isocitrate dehydrogenases (IDH1 and IDH2)
that function in the TCA cycle to produce α-ketoglutarate (αKG) from isocitrate [165].
In 2008, Parsons et al. and colleagues sequenced 20,661 protein-coding genes in
glioblastoma multiforme (GBM) and found a number of genetic aberrations not
previously known to be present in GBM [190]. Of particular interest was a mutation in
the active site of IDH1 [190]. Studies have now shown that either IDH1 or IDH2 is
mutated in almost 80% of grade II and III glioblastomas and acute myeloid leukemias
(AML) [165]. Mutations in IDH1 are heterozygous; an indication that this mutation is a
gain-of-function event [165]. A year later, in 2009, Dang et al. and colleagues
discovered a single mutation at arginine 132 and instead of synthesizing αKG, mutated
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IDH1 is responsible for production of a completely new metabolite, R (-)-2hydroxyglutarate (2HG) [191]. Moreover, this onco-metabolite, in excess, results in a
higher risk of formation and progression of glioblastoma and AML [165, 191]. Thus,
the presence of a tumor-specific metabolic alterations such as a mutations in IDH1
yields a valuable screening protocol for patients as well as a providing a plausible
treatment strategy, inhibiting 2HG production.
Lastly, although rare, mutations in succinate dehydrogenase (SDH) and
fumarate hydratase (FH) occur in pheochromocytoma, paraganglioma, leiomyoma, and
renal carcinoma [166, 192]. Elevated levels of succinate and fumarate are the results
of SDH and FH mutations and succinate specifically deregulates PHD3, an αKGdependent enzyme responsible for regulating HIF1α stability [192]. Similarly, fumarate
can deregulate PH2, but is also responsible for negative regulation of the transcription
factor, Nrf2, leading to anti-oxidant gene upregulation [192].
3.1d. Therapeutic targets in metabolic pathways
Eradicating tumor cells and leaving normal cells unharmed is the challenge of
modern cancer therapy. Indeed, tumor cells undergo a ‘metabolic transformation’ that
aids in proliferation and survival; and consequently, renders altered metabolic
pathways susceptible to inhibition (Figure 12) [193]. About 20 years after Otto Warburg
described aberrant glycolysis in cancer cells, the first antimetabolites were used in
cancer therapy [193, 194]. Farber et al. and colleagues used a folic acid antagonist
and observed temporary remission of acute leukemia in children [194]. Since then a
number of inhibitors of either metabolic enzymes or inhibitors of metabolic pathways
have been generated to target these ‘metabolically transformed’ cells (Table 8) [193].
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MK-0646

IGF1R

GLUT1
Lonidamine,
2-deoxyglucose,
3-bromopyruvate

PI3K

GDC-0941,
BEZ235,
XL765

Akt

Perifosine

Phloretin

Glucose

HK2

5-FU, Capecytenbine,
Cytarabine, Gemcitabine,
Clofaribine, Mercaptopurine,
Methotrexate

Metformin

AMPK
Glucose-6phosphate

Nucleotides

Phosphoenol
-pyruvate
TLN-232

mTOR

Cell proliferation, cell growth
and protein synthesis

Raplogues,
Torin1,
PP242,
BEZ235,
XL765

PK

Fatty
Acids

Pyruvate
SB-204990

FASN

ACLY
Lactate

TCA

Citrate

Acetyl-CoA
GSK837149A
C75
Orlistat

Figure 12. Therapeutic targets in metabolic pathways
Metabolic pathways that control growth and proliferation or provide macromolecular
intermediates are attractive targets for intervention. PI3K/Akt/mTOR inhibitors
indirectly impact metabolic pathways by inhibiting cell growth, proliferation and survival.
Direct targets of metabolic enzymes reduce the yield of pathway output leading to a
reduction in macromolecular intermediates required for cell proliferation. (Adapted from:
Tennant, D.A., R.V. Duran, and E. Gottlieb, Targeting metabolic transformation for
cancer therapy. Nat Rev Cancer, 2010. 10(4): p. 267-77.)

	
  

78	
  

Table 8: Inhibitors of metabolic enzymes or effectors of common
pathways
Compound

2deoxyglucose

Target

Hexokinase

Effect

Stage of
approval

Inhibits
glycolysis
Inhibits
glycolysis

Phase
I&II

Lonidamine

Hexokinase

3bromopyruvat
e

Hexokinase

Inhibits
glycolysis

Pyruvate
Kinase

Inhibits
glycolysis

Phase II

Nucleotide
biosynthetic
pathway

Inhibits
cell
proliferation

FDA
approve
d

IGF1R

Blocks IGF
signaling

Phase
I&II

IGF1R

Blocks IGF
signaling

Phase
I&II

AVE1642

IGF1R

Blocks IGF
signaling

Phase
I&II

GDC-0941

PI3K

PX866

PI3K

Inhibits
PI3K
signaling
Inhibits
PI3K

TLN-232
Antimetabolites
(i.e. 5-FU,
cytarabine,
methotrexate)
MK-0646

BIIB022
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Phase
III
Preclinical

Types of
cancers
Lung,
breast,
prostate,
gastic,
head and
neck
Benign
prostatic
hyperplasia
N/A

Study number(s)

•
•
•

NCT00633087
NCT00096707
NCT00247403

•
•

NCT00435448
NCT00237536
N/A

Metastatic • NCT00735332
melanoma
and renal
cell
carcinoma
Multiple
>100
cancer
types

•

NCT00799240

•

NCT00555724

•

NCT00791544

Phase
I&II

Lung,
pancreas,
liver,
breast
Lung,
pancreas,
liver,
breast
Lung,
pancreas,
liver,
breast
Breast,
lymphoma

•

NCT00876109

Phase
I&II

Breast,
lymphoma

•

NCT00726583

BEZ235

XL765

SF1126

	
  

PI3K/mTOR

PI3K/mTOR

PI3K/mTOR

BGT226

PI3K/mTOR

Torin1

mTORC1
and
mTORC2

PP242

mTORC1
and
mTORC2

Periforsine

Akt

GSK690693

Akt

PX-478

HIF1α

signaling
Inhibits
signaling
from PI3K
and
mTORC1
and
mTORC2
Inhibits
signaling
from PI3K
and
mTORC1
and
mTORC2
Inhibits
signaling
from PI3K
and
mTORC1
and
mTORC2
Inhibits
signaling
from PI3K
and
mTORC1
and
mTORC2
Inhibits
mTORC1
and
mTORC2
Inhibits
mTORC1
and
mTORC2
Inhibits Akt

Phase
I&II

Phase
I&II

Phase
I&II

Phase
I&II

•

NCT00485719

Advanced
solid
tumors
(i.e. lung,
brain

•

NCT00777699

Advanced
solid
tumors
(i.e. lung,
brain

•
•

NCT00704080
NCT00907205

Advanced
solid
tumors
(i.e. lung,
brain

•

NCT00600275

Preclinical

N/A

N/A

Preclinical

N/A

N/A

Phase
I&II

Inhibits Akt

Phase
I&II

Inhibits HIF

Phase I
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Advanced
solid
tumors
(i.e. lung,
brain)

Renal
cancer,
lung,
lymphoma
Renal
cancer,
lung,
lymphoma
Advanced

•
•

NCT00399789
NCT00399152

•

NCT00493818

•

NCT00522652

signaling

Acriflavine

HIF1α

Metformin

AMPK
complex and
Complex I of
mitochondria

SB-204990

ATP-citrate
lyase

Orlistat

FASN

GSK837149A

FASN

C75

FASN

solid
tumors
and
lymphoma
N/A

Inhibits HIF
signaling
Activates
AMPK

Preclinical
Phase
I&II

Inhibits fatty
acid
synthesis
Inhibits fatty
acid
synthesis
Inhibits fatty
acid
synthesis
Inhibits fatty
acid
synthesis

Preclinical

N/A

N/A

Preclinical

N/A

N/A

Preclinical

N/A

N/A

Preclinical

N/A

N/A

Solid
tumors
and
lymphoma

N/A
•
•
•
•
	
  

NCT00659568
NCT00881725
NCT00984490
NCT00909506

Adapted from:
Tennant, D.A., R.V. Duran, and E. Gottlieb, Targeting metabolic transformation for cancer
therapy. Nat Rev Cancer, 2010. 10(4): p. 267-77.
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Growth signaling pathway inhibitors such as those targeting IGF1R, PI3K and
Akt are used as an indirect method to target tumor cell metabolism and have had
success in decreasing cancer cell progression [195]. One of the most well known
metabolic drugs identified that is clinically used is metformin, an AMPK activator.
Metformin was first used in patients with type 2 diabetes; however, a study found that
diabetes patients that were treated with metformin had a higher probability of being
cancer-free after an 8-year follow-up compared to patients treated with other regimens
[193, 196]. These results were corroborated in preclinical mouse models as well as in
diabetes patients with breast cancer and found that metformin has a profound antitumor effect [193, 197, 198].
Another attractive target for intervention is glycolysis. As previously stated,
many tumor cells display elevated levels of glycolysis and greatly uptake glucose
regardless of bioenergetic requirement [165]. However, many inhibitors of glycolysis
used as a monotherapy, such as 2-deoxyglucose (a glucose mimetic which targets
hexokinase 2), are unsuccessful in osteosarcoma and NSCLC and require combination
treatment with either chemotherapy and/or radiotherapy [193, 199, 200]. For example,
2-deoxyglucose is synergistic when combined with adriamycin and paclitaxel in both
osteosarcoma and non-small cell lung cancer [199].
Moreover, the conversion of phosphoenolpyruvate to pyruvate by pyruvate
kinase is an important rate-limiting step of glycolysis and the PK inhibitor, TLN-232, is
currently in Phase II clinical trial [193]. However, TLN-232 is a PKM1 specific inhibitor
and as previously mentioned in chapter 3.1c, PKM2 is the predominant isoform of PK in
cancer cells. Recently, a PKM2 knockdown in a mouse model showed that PKM2 is
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not required for tumor growth in vivo and that other growth pathways may become
activated following its removal [201].
Another mode of intervention includes agents developed to reduce HIF1 levels
either by targeting effector molecules or by inhibiting HIF1 dimerization (Table 8) [193].
For example, acriflavine prevents dimerization between HIF1α and HIF1β subunits and
has been shown to be effective at inhibiting xenograft prostate cancer growth [193,
202]. Similarly, PX-478 has been shown to decrease HIF1α levels leading to a
profound inhibition of tumor growth both in vitro and in vivo in multiple cancer types
[193, 203].
Inhibition of the mTOR pathway is also an attractive target due to its overactivity
in multiple types of cancers [193]. Unfortunately, the mTOR inhibitor, rapamycin, and
its many rapalogues have had limited success as a monotherapy due to additional
activation of PI3K/Akt [193, 204]. Therefore, the creation of compounds targeting the
combination of mTORC1, mTORC2 and PI3K such as BEZ235 and XL765 have been
developed for lung and brain cancers and are currently in Phase I and II clinical trial
[193].
Lastly, cancer cells are largely dependent on de novo fatty acid synthesis for
their supply of fatty acids rather than from exogenous accumulation and as a
consequence, upregulate the de novo lipogenesis pathway [205]. The de novo
lipogenesis pathway will be described in more detail in Chapter 3.1e, however, agents
have been developed that target enzymes in this pathway; mainly inhibitors of fatty acid
synthase (FASN) and ATP-citrate lyase (ACLY) [193, 205]. FASN is overexpressed in
a variety of cancers, including cancers of the breast, colon and endometrium and the
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inhibition of FASN using C75, orlistat and GSK837149A, are very effective in vitro and
in vivo [206-208]. Additionally, FASN inhibitors have been used in combination with 5FU and traztuzumab to synergistically induce cell death [209, 210]. Likewise, ACLY is
overexpressed at the mRNA, protein and enzymatic level in lung adenocarcinoma
[153]. Inhibition of ACLY by either genetic or pharmacologic means, reduces glucosedependent lipid synthesis, proliferation and survival in vitro and in vivo [211]. ACLY will
be discussed in further detail in Chapter 3.1f and 3.1g. Ultimately, targeting metabolic
pathways and enzymes as a monotherapy or in combination in transformed cells
provides an effective avenue to target tumor-specific alterations and prevent toxicity to
normal tissues.
3.1e. The de novo lipogenesis pathway
In order to promote growth and proliferation, tumor cells are required to
synthesize macromolecular building blocks such as nucleotides, amino acids and fatty
acids. Fatty acids are derived from two sources: exogenously via dietary means and
endogenously via de novo synthesis [212]. The de novo lipogenesis pathway
synthesizes complex fatty acids such as phospholipids, triglycerides and
cholesterylesters that are important for synthesis of cell membranes and lipid-based
post-translational modifications on proteins [212]. In contrast to normal cells, tumor
cells obtain almost 93% of triacylglycerols from de novo synthesis [212]. Therefore,
enzymes of this pathway are commonly upregulated in a variety of cancers including
cancers of the ovary, breast, stomach, colorectum, lung, bladder and prostate among
others [212].
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GLUT1

Complex
fatty acids

GLYCOLYSIS

Glucose

Phospholipids
Triglycerides
Cholesterol esters
Acylated proteins

Palmitate

FASN
Malonyl-CoA

Acetyl-CoA

Pyruvate
ACC
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•
•
•
•

TCA

Pyruvate
Acetyl-CoA
Citrate

Citrate
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Figure 13. The de novo lipogenesis pathway
The de novo lipogenesis pathway is downstream of glycolysis and a truncated citric
acid cycle. Citrate is exported from the mitochondria into the cytoplasm and converted
to acetyl-CoA and oxaloacetate by ATP-citrate lyase (ACLY). Acetyl-CoA is used as a
substrate for Acetyl-CoA carboxylase (ACC) and synthesizes malonyl-CoA. Fatty acid
synthase (FASN) condenses malonyl-CoA and acetyl-CoA to form palmitate and other
complex fatty acids such as phospholipids, triglycerides, cholesterol esters. (Adapted
from: Menendez, J.A. and R. Lupu, Fatty acid synthase and the lipogenic phenotype in
cancer pathogenesis. Nat Rev Cancer, 2007. 7(10): p. 763-77.)
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The first enzyme of the lipogenesis pathway is ATP-citrate lyase (ACLY). ACLY
catalyzes the conversion of cytoplasmic citrate to acetyl-CoA and oxaloacetate
downstream of a truncated citric acid cycle (Figure 13) [205, 212]. Next, acetyl-CoA
carboxylase (ACC) synthesizes malonyl-CoA in a rate-limiting fashion [212]. In breast
carcinomas, ACC is overexpressed at the mRNA and protein level with its inhibition
resulting in decreased cell proliferation and cell viability [213-215]. The last reaction of
the pathway is the condensation of malonyl-CoA and acetyl-CoA by FASN to palmitate
and other complex fatty acids (Figure 13) [212]. Elevated levels of FASN are found in
over 20 types of cancer including breast, colorectal, bladder, ovary and lung [212].
Moreover, high FASN expression is also correlated with increased risk of disease
recurrence and death in breast cancer patients [208, 216].
3.1f. ATP-citrate lyase
As previously stated, ATP-citrate lyase (ACLY) catalyzes cytoplasmic citrate into
acetyl-CoA and oxaloacetate in the de novo lipogenesis pathway. In 2004, Beigneux et
al. and colleagues attempted to generate an ACLY knockout mouse by crossing ACLY
heterozygous mice [217]. However, no ACLY -/- mice were obtained from at least 60
litters and therefore, ACLY is required for embryonic development. Interestingly,
heterozygous mice were completely normal in spite of displaying only 50% of ACLY
mRNA and protein expression [217].
In mammals, ACLY is highly expressed in white adipose tissue and liver cells,
whereas brain, heart, small intestine and muscle cells display low levels of ACLY [218,
219]. Moreover, ACLY is localized primarily in the cytoplasm of cells to synthesize
acetyl-CoA in the de novo lipogenesis pathway, but recently has been found to be in
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the nucleus in murine embryonic fibroblasts, murine pro-B-cell lymphoid cells,
glioblastomas and in colorectal carcinomas [220]. In the nucleus, it has been proposed
that ACLY is responsible for acetyl-CoA production required for histone acetylation
[220].
Sterol regulatory element binding protein-1 (SREBP-1) is a lipogenic
transcription factor suggested to regulate the expression of lipogenic enzymes,
including ACLY, however, it found that ACLY mRNA levels do not correlate with
SREBP-1 levels [153]. Therefore, it was suggested that ACLY might be regulated not
at the transcriptional level, but post-translationally by phosphorylation and that the
phosphorylation may lead to enzyme activity and protein stability [153]. Indeed, ACLY
is phosphorylated by Akt on Ser454 in primary adipocytes as well as Thr 446 and Ser
450 by GSK3β in an insulin dependent manner [158]. However, Migita et al. and
collegues noted that ACLY phosphorylation and enzymatic activity were not completely
abolished and only exhibited a modest reduction when lung adenocarcinoma cells were
treated with the PI3K inhibitor, LY294002 [153]. Therefore, these data indicate that
ACLY activity may be regulated in part by another pathway.
3.1g. ATP-citrate lyase and cancer
ACLY has shown to be upregulated either at the protein level or the enzymatic
level in multiple cancer types including cancers of the lung, prostate, bladder, breast,
liver, stomach and colon [218]. Specifically in breast cancer, ACLY activity is 160 fold
higher in breast carcinoma compared to normal breast tissue [152]. Moreover, in lung
adenocarcinoma, ACLY is elevated at both mRNA and protein levels with high levels of
activated ACLY correlating with stage, grade and poor survival. In contrast, inhibition
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of ACLY at both genetic and pharmacologic levels has been effective at suppressing
proliferation and tumor growth in both in vitro and in vivo [211, 221]. These data
support the notion that increased ACLY expression and activity provide tumor cells with
selective growth advantages in order to support the tumorigenesis program.
3.1f. Hypothesis and specific aims
Metabolic transformation is a common feature of many tumor cells.
Upregulation of lipid synthesis as well as upregulation of lipogenic enzymes provide
tumor cells with essential building blocks required to maintain growth and survival in
unfavorable conditions. In the previous chapter, we found ACLY, a lipogenic enzyme,
to be a novel interacting protein of LMW-E in the cytoplasm. Therefore, we
hypothesize that LMW-E mediated tumorigenesis requires ACLY. The following
specific aims will address this hypothesis:
•

Examine LMW-E mediated changes of ACLY enzymatic activity.

•

Analyze lipid synthesis in an LMW-E inducible model system.

•

Determine the affects of ACLY knockdown on anchorage-independent growth,
migration and invasion of LMW-E expressing cells.

•

Examine the requirement of ACLY in xenograft tumor growth in LMW-E
expressing breast cancer cells.

Briefly, results presented in this chapter reveal that ACLY is regulated at the enzymatic
level by LMW-E. In addition to total ACLY activity increases, ACLY enzymatic activity
in the cytoplasm is elevated upon the induction of LMW-E and correlates with lipid
droplet formation; which is indicative of activation of the de novo lipogenesis pathway.
Moreover, ACLY is required for anchorage-independent growth, migration and invasion
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in LMW-E expressing cells. Lastly, ACLY is required for xenograft tumor growth of
MCF7 cells expressing LMW-E. Taken together, these data provide a unique insight of
how metabolic pathways and the cell cycle are intrinsically linked and will help
delineate treatment strategies for LMW-E expressing breast cancer patients.

3.2 MATERIALS AND METHODS
3.2a. Cell culture and plasmids
Human breast cancer MCF cells stably overexpressing cyclin E isoforms were
cultured as previously described [113]. The immortalized non-tumorigenic human
mammary epithelial cell line, 76NE6, which ectopically express cyclin E isoforms under
a doxycycline-inducible promoter were cultured as previously described [111, 112].
76NE6-tumor derived cells (TDCs) were generated and cultured as previously
described [111]. The shRNA constructs were purchased from the shRNA and
ORFeome core at the University of Texas MD Anderson Cancer Center (Houston, TX)
and were generated in a lentiviral packaging system as previously described [117].
Briefly, HEK293T cells were co-transfected with packaging vectors, pCMVΔR8.2 and
pMD2.G, along with either pGIPZ scrambled shRNA sequence or shACLY using
LipoD293T transfection reagent. Lentiviral supernatant was filtered through a 0.45µm
filter and transduced target cells for 48 hrs. Infected cells were selected with 0.5 µg/ml
(76NE6) or 2 µg/ml (MCF7) puromycin.
3.2b. Cell lysis, immunoblotting and kinase assays
Cell lysates were prepared and subjected to western blot analysis as previously
described in Chapter 2.2d. Western blots were incubated with primary antibodies
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against ACLY, Parp and β-tubulin (Cell signaling, Danvers, MA), cyclin E HE12 and
CDK2 were obtained from Santa Cruz Biotechnology (Dallas, TX), and β-actin was
obtained from EMB Millipore (Billerica, MA). For the kinase assay, lysates from MCF7
cells expressing the cyclin E isoforms and shRNA toward ACLY were
immunoprecipitated using a CDK2 antibody. Lysates were incubated with Histone H1
in kinase buffer containing 60 µM cold ATP and 5 µCi of [32P] ATP to a final volume of
30 µl at 37°C for 30 min. The products of the reactions were then analyzed on a 7%
SDS-PAGE gel. The gel was then stained, destained, dried, and exposed to X-ray film.
3.2c. In vitro transcription and translation (TnT)
Cyclin E isoforms and CDK2 proteins were generated according to the
manufacturers instructions using the TnT T7 Quick Coupled Transcription/Translation
System from Promega (Madison, WI).
3.2d. ACLY activity
ACLY activity was measured by the malate dehydrogenase-coupled method as
previously described [153]. Briefly, cell lysates were extracted from MCF7 and 76NE6
cell lines and incubated with the reaction mixture (200mM Tris Hcl pH 8.7, 20mM
MgCL2, 20mM potassium citrate, 1mM DTT, 0.2mM NADH, 1U/mL MDH, 0.5mM CoA)
with and without ATP and subjected to the assay. ACLY activity was measured every 3
minutes for 30 minutes using a NanoDrop 2000c spectrophotometer from Thermo
Scientific (Wilmington, DE). ACLY specific activity was calculated as the change in
absorbance with ATP minus the change in absorbance without ATP normalized to
protein concentration, however, 25ng was used in in vitro assays from utilizing purified
recombinant ACLY enzyme (US Biological, Salem, MA).
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3.2e. Cell fractionation
2 x 106 cells were plated on p150 tissue culture plates for 48 hours before
harvesting. To harvest cell lysates, cells were washed twice with PBS and removed
from the plate using a cell scraper in ice cold PBS. Cells were centrifuged at 2500rpm
for 5 minutes at 4°C. Cells were resuspended in RSB buffer (10mM Tris-HCl, pH 7.4,
10mM NaCl, 3mM MgCl2) and centrifuged at 2500rpm for 5 minutes at 4°C. Cells were
again resuspended in RSB buffer and homogenized using a loose fitting glass
homogenizer then passed through a 25-gauge syringe to break the cell membrane.
Lysate was incubated on ice for 10 minutes and centrifuged at 2500rpm for 5 minutes
at 4°C. The pellet is the nuclear fraction and the supernatant is the cytosol. The
supernatant was removed and placed in a clean tube. The pellet was washed with
RSB buffer and centrifuged again. The pellet was resuspended in 50µl Nuclear
Extraction Buffer (Cell Biolabs, San Diego, CA) along with 0.5µl of DL-dithiothreitol
(DTT) and 5µl protease inhibitors. The pellet was kept on ice for 30 minutes and
vortexed at the highest setting every 10 minutes. The pellet was centrifuged for 30
minutes at 14,000 x g at 4°C with the supernatant being the soluble nuclear fraction.
3.2f. Lipid staining
Lipid staining was conducted using the LipidTox reagent according to the
manufacturers instructions (Invitrogen, Grand Island, NY). Briefly, cells were fixed
using 4% paraformaldehyde and permeabilized with 0.1% saponin for 60 minutes at
room temperature. LipidTox reagent was diluted 1:200 in PBS and incubated with cells
for 45-60 minutes and imaged on an Olympus Epi-fluorescence microscope with a 60X
objective and Hamamatsu Orca camera.
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3.2g. Anchorage-independent growth assay
Anchorage-independent growth assays were performed as previously described
with the following modifications [222]. Briefly, MCF7 cells were plated at a density

of 2,500 cells/well on 12-well plates in 0.35% Seaplaque Agarose (Lonza,
Rockland, ME). Cells were grown for 10 to 30 days in their recommended
media and fed every 3-4 days. Colonies were measured by using the GelCount
system (Oxford Optronix, Abingdon, UK) with colonies greater than 50µm in
diameter scored. Three biological replicates were conducted in duplicate, with
results reported as average number ± SD.
3.2h. Migration assay
A total of 300,000 cells were plated on a 6-well tissue culture plate and allowed
to grow until confluent. The plate was then scratched with a pipet tip. Pictures were
taken at 0 and 24 hours using an EVOS XL Core light microscope with a 10X objective
(Life Technologies, Grand Island, NY) and scratch opening was measured using Adobe
Photoshop (San Jose, CA).
3.2i. Transwell invasion assay
The transwell invasion assay was performed as previously described [111].
Briefly, for each sample, 100 µl of 1 mg/ml Matrigel in serum-free cold MEM media was
placed into the upper chamber of 24-well transwell plate (Corning, Corning, NY) and
incubated at 37°C for 4–5 hours. Trypsinized cells were washed and suspended in
serum-free medium at a concentration of 1×106 cells/ml. 100µl of cell suspension was
transferred onto the upper chamber, while the lower chamber contains 600 µl of
complete media containing 10µg/ml fibronectin. After 24 hours, the cells were fixed
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and permeabilized with 4% formaldehyde for 15 minutes, rinsed with PBS three times,
incubated with 100% methanol for 20 minutes and washed again. The wells were
stained with 0.2% crystal violet for 15 minutes. The crystal violet was removed and the
invaded cells were photographed with an EVOS XL Core light microscope. Cells were
quantified by trypsinizing the cells and counted using a BioRad TC20 cell counter
(Hercules, CA). Each sample was repeated 3 times independently.
3.2j. Cell proliferation assay
Cells were seeded at a density of 1000 cells/well in a 96-well plate and
harvested every 24 hours for 96 hours. On day of harvest, 50µl per well of 2.5 mg/mL
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphentltetrazolium bromide) (Sigma) was added
to serum-free media and allowed to incubate at 37°C for 3 hours. After incubation,
media was removed and 100µl solubilization solution (0.04M HCl, 1%SDS, in
isopropanol) was added to each well. Plates were incubated with shaking for 1 hour
before reading on a plate reader (Epoch Microplate Spectrophotometer Gen 5
software, BioTek, Winooski, VT) at 590nm. Doubling time was calculated in Graphpad
Prism software (La Jolla, CA).
3.2k. Real-time PCR
Total RNA was isolated from cell culture with RNAeasy kit with DNase treatment
according to the manufacture's protocol (Qiagen). 2 µg of the RNA samples was
reverse-transcribed using cDNA synthesis kit (Applied Biosystems). Realtime PCR
was done with aliquots of the cDNA samples mixed with SYBR Green Master Mix
(Sigma). Reactions were carried out in triplicate. The fold difference in transcripts was
calculated by the ΔΔCT method using GAPDH as a control. E-cadherin forward 5’-
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TGCCCAGAAAATGAAAAA GG, reverse 3’-GTGTATGTGGCAATGCGTTC Twist
forward 5’-GGAGTCCGCAGTCTTA CGAG, reverse 3’-TCTGGAGGACCTGGTAGAG
G; Slug forward 5’- GGGGAGAAGCCTTT TTCTTG, reverse 3’TCCTCATGTTTGTGCAGG AG; and GAPDH forward 5’- ACCCAGAA
GACTGTGGATGG-3’, reverse 5’-CTGGACTGG ACGGCAGATCT-3’
3.2l. In vivo xenograft model
Nude mice were obtained from the department of Experimental Radiation
Oncology at The University of Texas MD Anderson Cancer Center (Houston, TX).
MCF7 cells were injected in a 50:50 ratio of cells:Matrigel at a density of 2.5 x 106
cells/mL in the mammary fat pad. Tumors were measured twice per week with caliper
starting at 3 weeks for 12 weeks.
3.2m. Statistical analysis
Experiments were performed in at least duplicate with at least three technical
replicates per experiment. All error bars are representative of standard deviation from
the mean Statistical analyses were performed using the Student’s t-test (two sample
equal variance; two-tailed distribution) using Graphpad Software, La Jolla, CA).

3.3 RESULTS
3.3a. LMW-E isoforms affects ACLY enzymatic activity
ACLY enzymatic activity has shown to be elevated in breast carcinoma and lung
adenocarcinoma compared to normal tissue [152, 153]. Therefore, we examined the
effect of cyclin E expression on ACLY enzymatic activity using the malate
dehydrogenase in human breast cancer cells that ectopically express the cyclin E
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isoforms. Expression of LMW-E(T1) and LMW-E(T2) significantly increased ACLY
enzymatic activity by 25-60% , while EL expression resulted in no change (Figure 14A).
Moreover, increased ACLY enzymatic activity was only detected upon doxycycline
induction of the LMW-E isoforms using the non-tumorigenic human mammary epithelial
cell line (hMEC), 76NE6; that contains inducible expression of cyclin E (Figure 14C).
The phosphorylation of ACLY on Ser454 by Akt is thought to regulate ACLY enzymatic
activity, however, the increase in ACLY enzymatic activity observed upon expression of
the LMW-E isoforms did not result in changes of total or phosphorylated ACLY protein
levels, indicating the increase in activity is independent of Akt (Figure 14B,D) [153].
Furthermore, examination of the LMW-E isoforms revealed that LMW-E(T1) and LMWE(T2) directly upregulate ACLY enzymatic activity 35-50%, while addition of EL or
CDK2 did not result in a significant increase of ACLY enzymatic activity (Figure 14E).
3.3b. Cytoplasmic ACLY activity results in lipid droplet accumulation
ACLY is primarily found in the cytoplasm, but has also been found to localize to
the nucleus in murine embryonic fibroblasts, murine pro-B-cell lymphoid cells,
glioblastomas and in colorectal carcinomas [220]. To examine whether the LMW-E
isoforms specifically upregulate cytoplasmic ACLY activity, 76NE6 cells with inducible
expression of cyclin E were fractionated and enzymatic activity was measured by the
malate dehydrogenase coupled method. ACLY enzymatic activity was higher in the
cytoplasm compared to the nucleus of all conditions examined, however, ACLY
enzymatic activity was increased by 40% in the cytoplasmic fraction of cells containing
LMW-E(T1) and LMW-E(T2) expression compared to uninduced conditions (Figure
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Figure 14. LMW-E isoforms affects ACLY enzymatic activity
(A) Stable expression of LMW-E isoforms increases ACLY enzymatic activity. ACLY
activity was determined by the malate dehydrogenase coupled method for 3
independent replicates. Error bars= SEM (Student’s t-test,**p<0.007). (B) Western
blot analysis showing protein expression. (C) Inducible expression of the LMW-E
isoforms increases ACLY enzymatic activity. ACLY activity was determined by the
malate dehydrogenase coupled method for 3 independent replicates. Error bars= SEM
(Student’s t-test,**p<0.004 and *p<0.03). (D) Western blot analysis showing protein
expression. (E) ACLY activity is shown from 2 independent replicates generated from
in vitro transcribed and translated proteins incubated with recombinant ACLY. Error
bars= SEM (Student’s t-test,**p<0.03).
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15B). Importantly, EL had no effect on activity, while nuclear LMW-E isoforms only
increase ACLY activity about 10% (Figure15B).
End products of the de novo lipogenesis pathway include phospholipids and
complex fatty acids resulting in lipid droplet formation [212]. Lipid droplets (LDs) are
intracellular structures comprised of a phospholipid and sterol outer layer and
hydrophobic core containing neutral lipids such as triacylglycerides and
cholesterylesters [223, 224]. Thus, lipid droplet stores provide building blocks for
membrane production, protein degradation, substrates for lipid-based post-translational
modifications and viral replication [224]. Therefore, to investigate lipid accumulation,
76NE6 cells containing inducible expression of the cyclin E isoforms were stained with
a neutral lipid dye. Neutral lipid staining under uninduced conditions showed a diffuse
pattern in all cyclin E isoforms, however, upon doxycycline induction, only LMW-E
expressing cells revealed a punctate pattern of neutral lipid staining indicating lipid
droplet formation (Figure 15C,D). LMW-E expression increased LD formation from
20% to 60% in LMW-E(T1) and from 20% to 45% in LMW-E(T2) expressing cells
(Figure 15 D).
Moreover, lipid droplet accumulation in LMW-E expressing cells requires ACLY.
Specifically, lipid droplets were present in only 20-30% of cells when ACLY is knocked
down, compared to 40-60% in control shRNA and indicates that expression of LMWE(T2) does not independently induce lipid droplet formation (Figure 15G,H). Together,
these data show that ACLY is highly active in the cytoplasm due to the presence of
LMW-E and results in lipid droplet formation in human mammary epithelial cells.
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Figure 15. Cytoplasmic ACLY activity results in lipid droplet accumulation
(A) Western blot showing protein expression from fractionated cells. (B) ACLY activity
is shown for 3 independent replicates from fractionated 76NE6 cells. Statistical
analysis was conducted using the student’s t-test. Error bars= SEM (**p<0.008 and
*p<0.04). (C) Intracellular lipid accumulation was measured using fluorescent dyes.
(D) Cells were counted for the formation of lipid droplets before and after addition of
doxycycline (n=100). Statistical analysis was performed using the student’s t-test
(*p<0.05). (E) Western blot showing protein expression. (F) ACLY activity is shown for
3 independent replicates. Error bars=SEM (**p<0.002). (G) Intracellular lipid
accumulation was measured using fluorescent dyes. (H) Cells were counted for the
formation of lipid droplets before and after addition of doxycycline (n=100). Statistical
analysis was performed using the student’s t-test (*p<0.05).
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3.3c. ACLY is required for LMW-E mediated transformation
The LMW-E isoforms are biologically hyperactive and display increased
tumorigenic potential compared to EL [113]. Therefore, to examine the requirement of
ACLY in LMW-E mediated tumorigenesis, an anchorage-independent growth assay
was performed in MCF7 cells containing knockdown of ACLY. Knockdown of ACLY
had no effect on vector cells and a slight reduction was observed in EL cells at 10 days,
but was rescued by 30 days (Figure 16D). Knockdown of ACLY in LMW-E expressing
cells resulted in colony formation being reduced up to 50% (Figure 16D). Moreover,
the average colony diameter was reduced by 20-40% in LMW-E expressing cells with
knockdown of ACLY (Figure 16E). Importantly, knockdown of ACLY did not affect
CDK2 associated kinase activity in cyclin E expressing cells, indicating that reduced
growth is not due to reduced proliferation in LMW-E expressing cells (Figure 16C).
Together, these data suggest that ACLY contributes to LMW-E mediated
transformation in the context of anchorage-independent growth.
3.3d. Inhibition of ACLY reduces migratory and invasive capabilities of HMECs
ACLY has been implicated in playing a role during migration in glioblastoma
[225]. In addition, it has been shown that LMW-E expression in non-tumorigenic
human mammary epithelial cells (76NE6-HMECs) that have been serially passaged
through mice; called tumor derived cells (TDCs), have an increased propensity to
invade using a transwell invasion assay [111]. Therefore, to examine whether ACLY is
required for LMW-E mediated migration and invasion in TDCs, ACLY was knockeddown using shRNA (Figure 17A,B). The wound healing assay showed that migration of
LMW-E expressing TDCs was significantly inhibited within 24 hours in the ACLY
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Figure 16. ACLY is required for LMW-E mediated anchorage-independent growth
(A) Western blot showing protein expression. (B) ACLY enzymatic activity in MCF7
cells containing shACLY. Error bars=SEM, **p<0.005. (C) CDK2 associated kinase
activity in knockdown cells. (D) Quantitation of colonies formed after 10 days and 30
days in anchorage-independent growth conditions. Statistical analysis was performed
using the student’s t-test. For 10 days *p<0.04,**p<0.009, ***p,0.0002. For 30 days
*p<0.04 and **p<0.0025. The assay was performed in triplicate with images from
whole wells from one representative experiment are shown. (E) Average colony
diameter. Statistical analysis was performed using the student’s t-test with **p<0.0085
and performed in triplicate with images from representative colonies are shown.
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Figure 17. Inhibition of ACLY reduces migration and invasion in HMECs
(A) Western blot analysis showing protein expression. (B) ACLY enzymatic activity in
76NE6 and TDCs containing shACLY. Error bars=SEM, *p<0.05, **p<0.009. (C)
Proliferation was assessed by MTT assay and read at 590nm. Doubling time was
calculated in GraphPad Prism software. (D) 76NE6 and TDCs containing either
scrambled shRNA or shRNA toward ACLY were allowed to reach confluency and
scratched. Images were taken at 0 and 24 hours post-scratch. (E) Quantitation of
migration assay. Statistical analysis was conducted using the student’s t-test from 3
independent replicates for each condition. Error bars=SEM; *p<0.05, **p<0.008. (F)
Cells were plated on a transwell chamber containing Matrigel and incubated on top of
fibronectin-containing media for 24 hours and invaded cells were stained with crystal
violet. Images of 20X magnification were taken with a light microscope. (G)
Quantitation of transwell invasion assay. Cells on the bottom of the transwell were
collected at 24 hours and counted. Statistical analysis was conducted using the
student’s t-test from 3 independent replicates for each condition. Error bars=SEM,
p<0.05,**p<0.005. (H) qRT-PCR for selected EMT related genes. Reactions were
carried out in triplicate with the fold difference in transcripts was calculated by the
ΔΔCT method using GAPDH as a control.

	
  

106	
  

knockdown cells, while vector control and EL had no effect (Figure 17C,D).
Specifically, migration was reduced in 76NE6-T1 shACLY cells by 50% and up to 30%
in ACLY knockdown TDCs. Importantly, reduced migration was not due to changes in
the proliferative capacity of the ACLY knockdown cells, as no changes were observed
in doubling time (Figure 17E). Moreover, using the transwell invasion method, indeed,
ACLY is required for LMW-E TDC mediated invasion. The invasive capacity of LMW-E
TDCs was reduced up to 60%, with minimal or no effect in vector or EL cells containing
knockdown ACLY (Figure 17F,G). LMW-E TDCs have also been reported to undergo
EMT, however, ACLY is not required for this process. Examination of EMT related
genes such as E-cadherin, Twist, Slug and Zeb1 displayed no change when ACLY was
inhibited (Figure 17H). Together, these data demonstrate that ACLY is required for
migration and invasion of LMW-E expressing TDCs and that proliferation and the EMT
process are unaffected.
3.3e. ACLY is required for LMW-E mediated tumor growth
To further examine the requirement of ACLY in LMW-E mediated tumorigenesis,
we performed an in vivo xenograft tumor assay and injected MCF7 cells containing
both stable expression of the cyclin E isoforms and stable knockdown of ACLY into the
mammary fat pad of nude mice. Knockdown in MCF7 vector cells displayed a modest
reduction in tumor growth, while knockdown of ACLY in EL expressing cells were
uninhibited (Figure 18A). Knockdown of ACLY in LMW-E expressing cells, however,
displayed substantial inhibition of tumor growth (Figure 18A). Specifically, on average,
vector expressing cells increased in volume about 3-fold and EL expressing cells
increased in volume about 6-fold, however, LMW-E expressing cells containing
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Figure 18. ACLY is required for LMW-E mediated tumor growth
(A) Inhibition of tumor growth in MCF7 cells containing stable overexpression of the
cyclin E isoforms and either scrambled shRNA or shRNA targeted to ACLY. Cells were
injected at a concentration of 2.5x106cells/100µL into the mammary fat pad of nude
mice. Tumors were measured for 12 weeks starting at 3 weeks. Statistical analysis
was conducted using the student’s t-test. N=5; error bars=SEM; **p<0.008 and
***p<0.0007. (B) Representative pictures of #12shACLY tumors and quantitation of
tumor weights. . Statistical analysis was conducted using the student’s t-test. Error
bars=SEM; *p<0.05, ***<0.0002 and ****p<0.0001. (C) Propensity of tumor growth.
LMW-E expressing cells containing knockdown of ACLY have delayed tumor latency.
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knockdown of ACLY exhibited virtually no change in tumor volume over the 12 week
period (Figure18A). These changes were corroborated with examination of tumor
weight, in that LMW-E expressing cells with knockdown of ACLY were extremely small
with weights ranging in size from 6mg-65mg (Figure 18B). Moreover, knockdown of
ACLY in LMW-E expressing cells delays tumor latency. Specifically, transcript #12
delayed tumor formation to 6 weeks in LMW-E(T1) and up to 9 weeks in LMW-E(T2)
expressing cells. Similarly, tumor formation was delayed in transcript #13, with only
40% of tumors forming after 12 weeks (Figure 18C). Taken together, these data show
that ACLY is required for LMW-E mediated tumor formation and tumor growth.

3.4 CONCLUSIONS
Energy deregulation is now recognized as a hallmark of cancer cells and a
characteristic of the transformed phenotype [162]. Indeed, metabolic enzymes have
been shown to be deregulated in cancer cells including deregulation of enzymes in the
de novo lipogenesis pathway [223]. Specifically, lipogenesis enzymes, ACC and
FASN, have shown to have elevated expression in breast and prostate cancers [223].
Moreover, ACLY has shown to be upregulated either at the protein level or the
enzymatic level in multiple cancer types including cancers of the lung, prostate,
bladder, breast, liver, stomach and colon [218].
This study demonstrates, for the first time, a direct link between the metabolic
enzyme, ACLY, with cell cycle protein, cyclin E. Specifically, the LMW-E isoforms
significantly increased ACLY enzymatic activity in human breast cancer, MCF7 cells,
and non-tumorigenic human mammary epithelial cells. Other studies have shown that
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ACLY enzymatic activity is mediated by phosphorylation by Akt [153]. However, in lung
adenocarcinoma A549 cells treated with the PI3K inhibitor, LY294002, showed only
partial inactivation of ACLY enzymatic activity, suggesting additional mechanisms of
ACLY activation [153]. We propose that ACLY is also enzymatically regulated by the
LMW-E isoforms.
Moreover, LMW-E mediated activation of ACLY is specific to cytoplasmic ACLY
and results in lipid droplet formation. Lipid droplets are energy reservoirs that provide
cells with the substrates required to support cell growth, proliferation, energy
homeostasis, resistance to oxidative stress and function in signaling [223]. Therefore,
these data indicate that LMW-E activation of ACLY and subsequent formation of lipid
droplets provides LMW-E expressing cells the necessary building blocks to sustain
growth.
Additionally, ACLY has been implicated in playing a role during migration in
glioblastoma [225]. In 76NE6-TDCs with LMW-E expression, knockdown of ACLY
significantly reduced migration and invasion with migration reduced up to 30% and
invasion reduced up to 60%. Changes in EMT related gene expression where not
detected, therefore, the reduced migratory and invasive phenotype may be due to
changes in lipid-based signals. Indeed, eicosanoids, phosphoinositides and
sphingolipids are signaling lipids shown to mediate multiple cellular processes such as
cell proliferation and migration [226]. It would be interesting to determine whether
changes in migratory behavior of LMW-E TDCs with ACLY expression was due to
depletion of these key lipid signaling molecules.
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Lastly, ACLY is required for LMW-E mediated tumor growth in vitro and in vivo.
Knockdown of ACLY in MCF7 cells expressing the LMW-E isoforms significantly
reduced anchorage-independent growth as early as 10 days with colony diameter after
30 days being reduced up to 40%. Moreover, reduced colony formation was
irrespective of CDK2-associated kinase activity, as kinase activity was only moderately
inhibited in vector cells containing knockdown of ACLY. Moreover, inhibition of ACLY
in LMW-E expressing cells significantly reduced tumor formation in vitro. Nude mice
bearing xenograft tumors expressing the LMW-E isoforms and containing knockdown
of ACLY exhibited substantial inhibition of tumor formation and tumor growth, while
knockdown of ACLY in vector cells had minimal reduction in tumor growth. No
inhibition of tumor growth was observed in EL expressing cells containing knockdown
of ACLY. These data indicate that LMW-E expressing tumors rely on ACLY and
presumably through the de novo lipogenesis pathway to support tumor growth and
formation. Taken together, LMW-E mediated activation of ACLY serves as a
mechanism of LMW-E mediated tumorigenesis and inhibition of ACLY may serve as a
viable target in breast cancers and other cancers with LMW-E expression.
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CHAPTER 4: CONCLUSIONS AND FUTURE DIRECTIONS

4.1 CONCLUSIONS AND MAJOR FINDINGS
Deregulation of the LMW-E isoforms leads to tumorigenesis and research
provided in this dissertation has addressed the primary hypothesis that aberrant
localization the LMW-E isoforms leads to molecular interactions that ultimately
contribute to LMW-E breast cancer tumorigenicity. The evidence delineated in this
dissertation has provided answers to the key questions outlined in chapter 1.
1. Does LMW-E have protein-binding partner(s) in the cytoplasm?
•

Indeed, using a retrovirus-based protein complementation assay, we found
11 novel interacting proteins of LMW-E. One of the interacting proteins
identified, ATP-citrate lyase (ACLY), is capable of directly binding all cyclin E
isoforms, but is not a substrate of cyclin E/CDK2.

2. Are the function(s) of the LMW-E cytoplasmic binding partner(s)
enhanced and/or suppressed?
•

Expression of the LMW-E isoforms elevates ACLY enzymatic activity in
breast cancer cells and non-tumorigenic human mammary epithelial cells.
Moreover, in cyclin E inducible cells, we found that activation of ACLY by
LMW-E occurs in the cytoplasm and results in lipid droplet formation, a
cellular energy reservoir important for providing lipid/energy substrates
required to fuel many cellular processes.

3. Are cytoplasmic LMW-E binding partners required for LMW-E mediated
transformation, invasive capabilities and tumor growth?
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•

Downregulation of ACLY impairs anchorage-independent growth in MCF7
cells expressing LMW-E, but not in control cells or EL expressing cells.
Migration and invasion are also diminished when ACLY is downregulated,
that is irrespective of the EMT program. In vivo, we found that
downregulation of ACLY in LMW-E expressing cells is required for tumor
growth and well as tumor formation.

4.2 FUTURE DIRECTIONS
Research provided in this dissertation contributes to the body of work
addressing the mechanisms of LMW-E induced tumorigenesis. While data presented
here advanced our knowledge by identifying cytoplasmic LMW-E binding proteins, due
to the number of binding protein identified, it is clear that LMW-E mediated
tumorigenesis is multifocal with many pathways and/or proteins contributing to LMW-E
mediated tumorigenicity. Therefore, further investigation is required; particularly
examination of the metabolic requirements of LMW-E expressing breast cancer cells.
From the RePCA screen, three metabolic proteins where identified as
cytoplasmic binding partners of LMW-E (T1): trans, 2,3-enoyl-CoA reductase (TECR),
Aldolase A (ALDO-A) and ATP-citrate lyase (ACLY). TECR functions in lipogenesis to
reduce long chain and very long chain fatty acids [148]. Exome sequencing revealed a
mutation that converts a leucine residue to a proline residue that is implicated in
autosomal recessive non-syndromic mental retardation (NSMR), but no known link to
cancer has been established [227]. ALDO-A, on the other hand, has been linked to
human neoplasias. ALDO-A functions in glycolysis to catalyze the conversion of
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fructose-1,6-bisphosphate to glyceraldehyde-3-phosphate and dihydroxyacetone
phosphate [228]. For example, in Ras transformed NIH-3T3 cells, ALDO-A inhibition
by siRNA resulted in a reduction in cell proliferation upwards of 90% [229]. Moreover,
malignant adrenocortical tumors exhibit high expression of ALDO-A compared to
benign tumors and high expression of ALDO-A in lung squamous cell carcinoma
(LSCC) correlates with poor prognosis, reduced differentiation and increased tumor
grade [228, 230].
Since multiple metabolic enzymes from different pathways were identified in the
RePCA screen, it is plausible that LMW-E expressing cells broadly deregulate cellular
metabolism and exploit flux through glycolysis and the de novo lipogenesis pathway.
Glucose uptake is a characteristic of a more aggressive breast cancer phenotype and
in general, MCF7 cells are less aggressive [177]. However, it can be hypothesized that
breast cancer cells containing LMW-E expression shift to a more glycolytic phenotype
since LMW-E expression renders breast cancer cells more aggressive and have a poor
prognosis compared to breast cancer cells only containing expression of full-length
cyclin E (EL) [98, 109, 111, 231]. Therefore, examination of glucose uptake in LMW-E
expressing cell would provide additional insight regarding the metabolic alterations in
LMW-E expressing breast cancer cells.
We also found that LMW-E expression results in lipid droplet formation. Lipid
droplets (LDs) are intracellular energy reservoirs composed of triacylglycerides and
cholesterylesters surrounded by a phospholipid monolayer [223]. LDs and increased
fatty acid synthesis have shown to be involved in many areas of cancer progression
[223]. In general, fatty acids promote membrane synthesis important for cell growth
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and proliferation, but also exhibit non-proliferative roles. For example, fatty acids lead
to membrane saturation important for resistance to oxidative stress and survival under
energy stress [223]. Additionally, metabolic intermediates such as NADPH provide
redox balance and fatty acid derived lipids facilitate signaling through membrane
receptors or lipid-based posttranslational modifications [223]. Since knockdown of
ACLY did not affect proliferation in LMW-E expressing 76NE6 human mammary
epithelial cells, LDs with respect to LMW-E may play a non-proliferative role. We
showed that knockdown of ACLY resulted in reduced migration and invasion that may
be due to decreased fatty acids that regulate these functions. For example, watersoluble phospholipid, lyosophosphatidic acid (LPA), has shown to promote migration
through G-protein-coupled receptors and the PI3K pathway [223, 232]. Furthermore,
prostaglandins derived from cyclooxygenase 2 (COX2), also promote migration and
support tumor-microenvironment interactions [233]. Preliminary examination of these
lipid signaling molecules may prove to be involved in LMW-E mediated migration and
invasion.
Another function of LDs is resistance to oxidative stress [223]. Activation of de
novo lipogenesis results in an intracellular increase of saturated and mono-unsaturated
phospholipids that are more resistant to peroxidation while decreasing poly-unsaturated
phospholipids [234]. Therefore, inhibition of de novo fatty acid synthesis or inhibition of
lipogenic enzymes has been shown to sensitize cells to oxidative stress causing cell
death [234]. Moreover, decreased membrane saturation enables diffusion of
chemotherapeutic agents such as doxorubicin; thereby providing rationale for the
combination of lipogenesis inhibitors with chemotherapeutic agents [234].
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In addition to investigating the broad scope of metabolic deregulation in LMW-E
expressing breast cancer cells, the mechanism behind the LMW-E/ACLY interaction
has yet to be established. It can be hypothesized that ACLY binds cyclin E in the
MRAIL motif; which facilitates recognition of RXL containing proteins [81]. ACLY
contains three RXL regions of interest. The first RXL motif is located at the N-terminus
of ACLY, but is unlikely the site of cyclin E binding due steric hindrance by the ATP
grasp fold between domains 3 and 4 of ACLY [235]. The next RXL motif and the most
likely site of cyclin E binding, is found in the highly variable region of ACLY (aa426486). It is within this region ACLY is phosphorylated by multiple kinases including Akt
and GSK3β [158]. This RXL motif lies just 27 amino acids downstream of S454, the
site of phosphorylation by Akt [158]. The final RXL motif in ACLY is located within
domain 1 which binds CoA [235]. Due to the power helices fold between domains 2
and 5, domain 1 is probably not easily accessible to a large protein such as cyclin E
and can also be ruled out due to steric hindrance.
Since ACLY binds all isoforms of cyclin E (EL, LMW-E(T1) and LMW-E(T2)), it is
logical that ACLY would bind in a common region of all cyclin E isoforms and not the Nterminus; which LMW-E are lacking. CDK2 binds cyclin E through the cyclin box motif
and the last 50 amino acids [82]. It is possible that ACLY requires multiple regions on
cyclin E to bind as well. Therefore, truncations of cyclin E can be generated to
examine this possibility. Lastly, if ACLY binds cyclin E in the cyclin box, it is possible
that ACLY has affinity to other cyclins as well since the cyclin box is a conserved region
shared among all cyclins [75]. To examine this possibility, co-immunoprecipitation
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assays can be performed to investigate interaction between ACLY and other cyclins
involved in the cell cycle such as cyclin D, cyclin A or cyclin B.
Finally, we found that genetic downregulation of ACLY resulted in reduced
anchorage-independent growth in vitro and xenograft tumor growth in vivo that was
specific to LMW-E expressing breast cancer cells. Thus, in order to utilize this antitumor affect clinically, it would be imperative to examine whether pharmacologic
inhibition was equally effective. There are several competitive and non-competitive
inhibitors of ACLY [236]. Hydroxycitrate, one of the most studied competitive inhibitors,
has shown modest success [225, 237, 238]. Hydroxycitrate is derived from Garcinia
fruits and/or flowers and is commonly added to diet supplements, however, studies with
mice have shown no differences in regards to weight [158, 236]. The anti-neoplastic
effect of hydroxycitrate has been shown in bladder and colon carcinoma cell lines with
growth inhibition ranging from 5-60% [238].
Butanedioic acid derivatives are another type of competitive inhibitor of ACLY
[236]. Specifically, SB-204990, the pro-drug of SB-201076, has shown to be effective
at reducing glucose-dependent lipid synthesis in vitro and tumor growth in vivo [211,
221]. Hatzivassiliou et al. and collegues report SB-204990 reduces lipid synthesis in a
dose-dependent manner in a murine pro-B-cell lymphoid cell line as well as a
significant reduction in xenograft tumor growth from mouse pancreatic ductal cell lines
containing K-RasG12D mutations [221]. Finally, non-competitive inhibitors of ACLY are
effective at inhibiting ACLY in vitro, with only a few examining the inhibitory effect in
vivo, but their toxicity is problematic and there is no evidence relating to their antineoplastic properties [236].

	
  

118	
  

4.3 SIGNIFICANCE
Breast cancer continues to be among the leading causes of cancer death in
women in the United States and the identification of the molecular mechanisms of
sporadic breast cancer remain largely elusive for this complex disease [1]. Breast
cancer patients that express high levels of LMW-E have a poor prognosis and this
dissertation identified ACLY, a cytoplasmic LMW-E binding protein, that mediates
breast cancer tumorigenicity [98]. Genetic inhibition of ACLY in LMW-E expressing
breast cancer cells attenuates tumor growth. Pharmacologic inhibition of ACLY in
LMW-E positive breast cancer patients has the potential to be a viable treatment
strategy to combat sporadic breast cancer. Moreover, inhibition of ACLY may prove to
be beneficial in targeting other cancer types that display LMW-E expression such as
ovarian, colorectal cancers and melanomas.
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